Progesterone action in breast, uterine, and ovarian cancers

Caroline H Diep[1], Andrea R Daniel[1], Laura J Mauro[3], Todd P Knutson[1] and Carol A Lange[1,2]

Hematology, Oncology, and Transplantation Division, Departments of [1]Medicine, and [2]Pharmacology, Masonic Cancer Center, University of Minnesota, Delivery Code 2812, Cancer Cardiology Research Building, 2231 6th Street SE, Minneapolis, Minnesota 55455, USA
[3]Division of Physiology and Growth, Department of Animal Science, University of Minnesota, Minneapolis, Minnesota 55108, USA

Correspondence should be addressed to C A Lange
Email
lange047@umn.edu

Abstract

Progesterone and progesterone receptors (PRs) are essential for the development and cyclical regulation of hormone-responsive tissues including the breast and reproductive tract. Altered functions of PR isoforms contribute to the pathogenesis of tumors that arise in these tissues. In the breast, progesterone acts in concert with estrogen to promote proliferative and pro-survival gene programs. In sharp contrast, progesterone inhibits estrogen-driven growth in the uterus and protects the ovary from neoplastic transformation. Progesterone-dependent actions and associated biology in diverse tissues and tumors are mediated by two PR isoforms, PR-A and PR-B. These isoforms are subject to altered transcriptional activity or expression levels, differential crosstalk with growth factor signaling pathways, and distinct post-translational modifications and cofactor-binding partners. Herein, we summarize and discuss the recent literature focused on progesterone and PR isoform-specific actions in breast, uterine, and ovarian cancers. Understanding the complexity of context-dependent PR actions in these tissues is critical to developing new models that will allow us to advance our knowledge base with the goal of revealing novel and efficacious therapeutic regimens for these hormone-responsive diseases.

Key Words
- progesterone
- progestin
- progesterone receptor
- isoforms
- breast cancer
- endometrial cancer
- uterine
- ovarian cancer

Journal of Molecular Endocrinology
(2015) **54**, R31–R53

Journal of Molecular Endocrinology

Introduction

Progesterone and progesterone receptors (PRs) are increasingly gaining attention for their emerging role as critical regulators of breast and gynecological cancers. With this newfound spotlight on PR action, there is an urgent need to define the mechanisms by which progesterone and progestins exert their effects upon tumor types in different PR+ tissues and bring clarity to areas of confusion in the field. Much of the difficulty lies in the nuanced context-dependent actions of PR, the different isoform-specific actions of PR-A relative to PR-B (PR isoforms are not measured separately in the clinic), the differential or potential off-target actions of synthetic progestins (i.e., used clinically) vs natural progesterone, and the seemingly paradoxical biological effects that progesterone exerts on the breast vs gynecological tissues. In the breast, progesterone is proliferative and works in concert with estrogens and estrogen receptors (ERs) to induce expansion of glandular structures during development (reviewed in Brisken & O'Malley (2010)). Progesterone is a key mediator of mammary gland stem cell expansion (Brisken 2013). In the presence of estrogen, ER-induced expression of PR is required to induce proliferation by both autocrine and paracrine mechanisms (Brisken 2013); PR-target genes include secreted factors (wnt4) that act on nearby

http://jme.endocrinology-journals.org
DOI: 10.1530/JME-14-0252

Published by Bioscientifica Ltd.

PR-negative cells. In contrast to ER and PR cooperative actions in the breast, progesterone opposes ER actions in the ovary and endometrium, and acts in an antiproliferative manner to induce tissue regression (Kim & Chapman-Davis 2010). Our goal herein is to examine the relevant literature, clarify the rhetoric, and identify the gaps in our knowledge that require further inquiry.

Progesterone is a steroid hormone that is produced primarily by the corpus luteum in the ovaries during the second half of the menstrual cycle or luteal phase. Progesterone is also produced, to a lesser extent, in the adrenal glands and, during pregnancy, the placenta. Thus, cyclical hormone exposure beginning at menarche and ending in menopause occurs monthly and regulates the growth and differentiation of specialized tissues within the reproductive tract and breast tissues (Lydon *et al*. 1995, Graham & Clarke 1997). Pregnancy interrupts this process and is characterized by high progesterone levels, which are required for fetal development, breast development for lactation, maintenance of uterine/placental integrity, and myometrial quiescence (Mendelson 2009).

Expression of PR in responsive tissues is driven by estrogen-bound ER and, therefore, ER is permissive for the actions of PR and progesterone. As a result, one experimental challenge that researchers face in determining the actions of PR is their differentiation from those of ER. Elegantly designed mouse models and transplant studies have delineated the developmental processes attributed to each receptor (reviewed in Brisken & O'Malley (2010)). Briefly, PR-B is the predominant isoform required for mammary gland development and expansion, whereas PR-A is necessary for proper uterine development and reproductive actions (Conneely *et al*. 2001). PR expression is limited to 10–15% of mammary luminal cells and primarily signals in a paracrine manner to induce proliferation of steroid receptor-negative cells (Brisken *et al*. 1998). PR-containing cells proliferate autonomously during periods of massive glandular expansion, such as pregnancy. PR is expressed in both the epithelial and stromal compartments of the breast and uterus and signals in both paracrine and autocrine manners to affect biology (Kim & Chapman-Davis 2010, Brisken 2013, Kim *et al*. 2013). The actions of progesterone and its isoforms in normal physiology of the breast (see Kariagina *et al*. (2008)), uterus (see Kim *et al*. (2013)), and ovary (see Modugno *et al*. (2012)) have been extensively reviewed previously.

PRs are members of the steroid hormone family of nuclear receptors and as such are composed of a modular domain structure that includes an N-terminal domain (NTD), DNA-binding domain (DBD), hinge region (H), and hormone-binding domain (HBD) (Fig. 1). There are three PR isoforms: full-length PR-B, N-terminally truncated PR-A (−164 amino acids), and the non-functional PR-C, consisting of only the hinge region and HBD (Fig. 1). PR-B and PR-A are typically expressed in equimolar ratios and function as ligand-activated transcription factors, whereas expression of PR-C is limited and may serve largely to sequester ligand, as it is incapable of binding DNA (Condon *et al*. 2006).

Progesterone diffuses through the lipid membrane and interacts with the HBD of PR-A or PR-B. This interaction alters the confirmation of PR favoring nuclear localization, dimerization (A:A, B:B, or A:B dimers are possible), and DNA binding. Classically, PR binds progesterone response elements (PREs) in the DNA and recruits cofactors and transcriptional machinery to initiate gene transcription. PR can also participate in the transcriptional complexes of other DNA-bound transcription factors to alter gene expression (Owen *et al*. 1998, Stoecklin *et al*. 1999, Cicatiello *et al*. 2004, Faivre *et al*. 2008). Nonclassical or extranuclear signaling of PR involves direct binding of PR to kinases complexed at the membrane with growth factor receptors (such as EGFR or IGF1R) to initiate rapid activation of downstream signaling cascades (Migliaccio *et al*. 1998, Boonyaratanakornkit *et al*. 2001). For example, progesterone induces rapid activation of ERK1/2 MAPK pathways, which function to activate a variety of transcription factors via phosphorylation events, including PR itself (Migliaccio *et al*. 1998, Boonyaratanakornkit *et al*. 2001, Faivre *et al*. 2008; Fig. 1). Notably, PR-B, but not PR-A, is capable of rapid signaling, probably in part owing to its relatively increased occupancy in the cytoplasm (Boonyaratanakornkit *et al*. 2007). The regulation of gene programs driven by PR and progesterone is highly dependent on the local cellular environment and the intracellular signaling context. Thus, PRs act as 'sensors' of cell context, rapidly adjusting to hormonal fluctuation and integrating a variety of extracellular signals to enable tight control of developmental programs. The mechanisms by which PR selects and modulates genetic programs in response to variable external signals are discussed later in this review.

Breast

Proliferative actions of PR in the breast

Progesterone, acting through PR, is a critical mediator of mammary gland tissue expansion during breast

Journal of Molecular Endocrinology

http://jme.endocrinology-journals.org
DOI: 10.1530/JME-14-0252

Published by Bioscientifica Ltd.



Figure 1

The post-translational modifications of progesterone receptors. Seventeen post-translational modification sites that affect PR-mediated transcriptional action. PR-B, but not PR-A, includes 164 additional amino acids in the NTD (called B upstream segment), where the third activation function domain and multiple phosphorylation sites are located. PR-B and PR-A are transcribed from the same gene and their protein isoforms are identical to amino acids 165–993. The protein tertiary structure results in a folding at the hinge region between the DBD and HBD. Post-translational modifications (phosphorylation, acetylation, and SUMOylation) can occur basally or in response to ligand binding and affect PR transcriptional activity. In particular, activated protein kinase pathway input to PR via phosphorylation and these pathways are heavily altered in breast, ovarian, and uterine carcinomas. Numbering reflects amino acid residue positions. The color of phosphorylation sites is associated with the following: red, MAPK; green, CDK2; yellow, CK2; purple, unknown kinases. PR, PR protein isoforms A, B, or C; NTD, N-(amino)-terminal domain; DBD, DNA-binding domain; H, hinge region; HBD, hormone-binding domain; AF, activation function 1–3; P, phosphorylation; A, acetylation; SUMO, small ubiquitin-like modifier (SUMOylation). Dysregulation of Kinase Inputs to PR in Cancer: the percent of The Cancer Genome Atlas Research Network 2011 (TCGA) tumors containing alterations in MAPK, CDK2, or CK2 components was identified using the cBioPortal.org analysis tool. For analysis of dysregulated kinases: MAPK includes canonical c-Raf, Mek, and Erk signaling pathway genes: *RAF1*, *MAP3K1*, *MAP3K2*, *MAPK3*, *MAPK1*; *CDK2*, cyclin-dependent kinase 2; *CK2*, casein kinase 2; *CSNK2A1*, casein kinase 2, α 1 polypeptide.

development after puberty. Mouse models lacking PR-B, but not PR-A, exhibit marked defects in mammary gland branching and alveologenesis (Conneely *et al.* 2003), supporting the concept that PR-B is the predominant isoform required for mammary gland development and expansion. Interestingly, ER is also required for mammary gland proliferation during pubertal development (Daniel *et al.* 1987). However, in the adult mammary gland, proliferation occurs via the actions of PR at its primary target genes, while ER is necessary for PR expression (Brisken 2013). In hormone ablation and replacement studies in adult mice, ovariectomy arrests glandular proliferation. Exogenous estrogen alone provides a weak signal, whereas treatment with estrogen and progesterone restores glandular proliferation (Wang *et al.* 1990). Tissue transplant studies in genetically modified mice demonstrated that ER and PR induce proliferation in mammary gland structures primarily via paracrine signaling (Brisken *et al.* 1998). PR is expressed in both the epithelial and stromal compartments of the breast and is limited to 10–15% of mammary luminal cells (Brisken 2013). Progestin stimulation of PR-positive mammary epithelial cells induces transcription and secretion of multiple mitogenic factors, including Wnts, Areg, HB-EGF, and receptor activator of nuclear factor kappaB ligand (RANKL) that induce proliferation of neighboring PR-negative cells (Brisken 2013; Fig. 2). Recent evidence has implicated that these same PR signaling outputs (RANKL and WNT) are required for maintenance and expansion of the mammary gland stem cell compartment. Studies in mice blocking either PR or its downstream effector RANKL demonstrated a loss of mammary stem cell function and mammary cells expressing stem cell markers respectively (Asselin-Labat *et al.* 2006, Joshi *et al.* 2010). Furthermore, the importance of the PR–RANKL axis was confirmed in primary human tissue microstructures (Tanos *et al.* 2013). Recently, bi-potent human mammary progenitor cells have been shown to express PR, independent of ER (Hilton *et al.* 2012). Additionally, progesterone treatment of human mammary epithelial cells cultured as multi-cellular acini

http://jme.endocrinology-journals.org
DOI: 10.1530/JME-14-0252

Published by Bioscientifica Ltd.



Figure 2

Progesterone receptor action in the normal mammary gland. Pictured here in cross-section, alveoli are the primary glandular structures of the breast that form in groups (lobules) that are connected to the nipple through a network of ducts embedded within supporting stromal and adipose cells. Each alveolar unit contains a hollow lumen surrounded by a layer of apical luminal epithelium and basal myoepithelium (that are contractile and help with milk secretion during pregnancy). A basement membrane separates the epithelium from the surrounding adipose and stroma (that includes infiltrating immune cells, connective tissue, fibroblasts, and endothelium). The epithelium is derived and maintained from a population of self-renewing mammary stem cells. As illustrated in the inset, the majority of these mammary epithelial cells undergoing cell cycle progression (expressing cyclin D1) receive their proliferative signals via paracrine growth factor production (AREG, IGFs, and HBEGF) from nearby PR-positive cells. PR-positive cells also produce paracrine factors to maintain the mammary stem cell compartment, including WNT4 and RANKL. During early events in breast tumorigenesis, non-dividing PR+ cells (that express cell cycle inhibitors p21 and p27) may overcome cell cycle inhibition and actively begin proliferation via autocrine signaling. PR, progesterone receptor; AREG, amphiregulin; RANKL, receptor activator of nuclear factor κB ligand; WNT4, wingless-type MMTV integration site family, member 4; IGF, insulin-like growth factor; HBEGF, heparin-binding epidermal growth factor-like growth factor; D1, cyclin D1, CCND1; p21, cyclin-dependent kinase inhibitor 1A, CDKN1A; p27, cyclin-dependent kinase inhibitor 1B, CDKN1B; MaSC, mammary stem cell.

structures increased the progenitor cell population (Graham *et al.* 2009). These data, indicating that progesterone is a key source of self-renewal and replicative potential in the mammary gland, raise important questions about the contribution of PR and progesterone to the development of breast cancer and tumor progenitor cell maintenance.

Recent findings have implicated progesterone as a key mediator of breast cancer progenitor cell plasticity. Exposure of ER+/PR+ breast cancer cultures to progesterone induces the emergence of cells expressing known progenitor and stem cell markers, such as CK5 (KRT5) and CD44. These cells possess properties that include therapy resistance and heightened mammosphere-forming potential (Horwitz *et al.* 2008, Cittelly *et al.* 2013). PR regulation of microRNAs (miRs) facilitates the increase in stem-like phenotypes in breast cancer cell cultures. Downregulation of miR-29a facilitates dedifferentiation by releasing the transcription factor KLF4 to alter gene programs (Cittelly *et al.* 2013), while miR-141 repression by PR prevents downregulation of PR itself and STAT5 (STAT5A), which is known to control progenitor cell phenotypes (Yamaji *et al.* 2009). Notably, evidence is mounting in favor of the prevailing hypothesis that hormone replacement therapies (HRTs), which include progestins, induce a greater incidence in breast cancer by the expansion of pre-malignant stem cell populations (Horwitz & Sartorius 2008).

Indeed, epidemiological evidence and clinical findings have demonstrated that synthetic progestins, whether given in HRT as post-menopausal treatments or as hormonal contraceptives in pre-menopausal women, confer a greater breast cancer risk. Progestin-containing contraception is linked to an increased risk of developing breast cancer in multiple epidemiological studies (Collaborative Group on Hormonal Factors in Breast Cancer 1996, Hunter *et al.* 2010, Li *et al.* 2012, Soini *et al.* 2014). Similarly, other epidemiological studies indicate that greater exposure to progesterone throughout an individual's lifetime leads to greater likelihood of breast cancer (reviewed in Knutson & Lange (2014)). Large-scale clinical trials, including the Women's Health Initiative (hazard ratio 1.26; 95% CI 1.02–1.55) (Chlebowski *et al.* 2009), Million Women's Study (relative risk 2.00 (1.88–2.12), $P<0.0001$) (Beral 2003), E3N-EPIC cohort (relative risk 1.3 (1.1–1.5)) (Fournier *et al.* 2005), and Finnish Cancer Registry case-controlled analysis (odds ratio 1.36; 95% CI 1.27–1.46) (Lyytinen *et al.* 2010), demonstrate that women taking progestins added to estrogen therapy are at greater risk of developing breast tumors. Unexpectedly, estrogen alone as a single-agent therapy for women who have had a hysterectomy confers protection against breast cancer (hazard ratio 0.77; 95% CI 0.62–0.95) (Chlebowski & Anderson 2012). Recently, a retrospective analysis of Finnish women using the levonorgestrel-releasing intrauterine system of contraception has also demonstrated an increased risk of breast cancer (standardized incidence ratio for one purchase 1.16; 95% CI 1.09–1.22. For users with two purchases: 1.40; 95% CI 1.24–1.57) (Soini *et al.* 2014). However, the same regimen conferred protection from endometrial (for one purchase 0.50; 95% CI 0.35–0.70; for users with two purchases 0.25; 95% CI 0.05–0.73) and ovarian cancers (0.60; 95% CI 0.45–0.76) as well as lung (0.68; 95% CI 0.49–0.91) and pancreatic (0.50;

http://jme.endocrinology-journals.org
DOI: 10.1530/JME-14-0252

Published by Bioscientifica Ltd.

95% CI 0.28–0.81) cancers (Soini *et al*. 2014). In studies comparing HRT containing synthetic and natural progestins (albeit with smaller cohort sizes), natural progestins did not significantly increase breast cancer risk (Fournier *et al*. 2005, 2008). Importantly, the relative instability of natural progesterone may account for the differential biological outcomes compared with long-lived synthetic progestins, raising interesting questions about the duration and level of exposure to PR activators (reviewed in Brisken (2013)). Alternatively, synthetic progestins may elicit off-target effects on other steroid receptors that may also contribute to their deleterious or protective effects (reviewed in Knutson & Lange (2014)). Together, these epidemiological and clinical findings support the notion that uncontrolled PR action in pre-neoplastic breast tissue contributes to breast cancer development. These data are corroborated by an expansive body of literature demonstrating in both *in vivo* and *in vitro* models of luminal breast cancer that exposure to progestins increases proliferation and promotes pro-survival and progression of malignant breast cells (reviewed in Daniel *et al*. (2011)). Interestingly, while ~70% of newly diagnosed breast tumors are ER+/PR+ (luminal-type tumors), ~40 and 25% of luminal tumors exhibit loss of heterozygosity (LOH) at the PGR or ER locus respectively (Knutson & Lange 2014). Generally, ER and PR LOH are positively correlated. However, interestingly, despite this genetic loss, ER and PR mRNA levels remain very similar to that of diploid luminal tumors (Knutson & Lange 2014), suggesting that other compensatory factors may exist in these tumors to maintain ER and PR expression.

Context-dependent PR activation

The gene programs driven by PR are determined by a diverse array of cellular conditions that modify the receptor and its cofactors, which serve to direct transcriptional complexes to specific promoters. Not surprisingly, progesterone binding produces a dramatic shift in PR-mediated gene selection. PR remains bound to and regulates expression (both activation and repression) of a multitude of genes in the unliganded state (Knutson *et al*. 2012*a*, Daniel *et al*. 2014, Dressing *et al*. 2014), whereas PR relocates to a subset of progesterone-responsive genes upon ligand binding. These two broad categories of PR-driven genes, unliganded and liganded gene sets, are further regulated by the convergence of particular kinase pathway outputs (Fig. 1), in the form of direct phosphorylation of PR and its cofactors (reviewed in Hagan & Lange (2014)). For example, phospho-S294 PR, in response to MAPK or CDK2 activation, regulates an overlapping yet distinct set of gene targets in the presence of progesterone compared with phospho-S81 PR (via activated CK2), and the same (i.e., sensitivity of selected genes to phosphorylated PR) is true for unliganded target genes (Daniel *et al*. 2007, Daniel & Lange 2009, Hagan *et al*. 2011*a*, Knutson *et al*. 2012*b*). To date, post-translational modifications identified on PR that alter its transcriptional activity include: phosphorylation (S294, S345, S81, and S400), SUMOylation (K388), acetylation (K183, K638, K640, and K641), and ubiquitinylation (Fig. 1; Lange *et al*. 2000, Pierson-Mullany & Lange 2004, Daniel *et al*. 2007, 2010, Faivre *et al*. 2008, Daniel & Lange 2009, Beleut *et al*. 2010, Hagan *et al*. 2011*a*, Knutson *et al*. 2012*b*, Chung *et al*. 2014, Dressing *et al*. 2014). PR transcriptional activity and promoter selection are thus dramatically altered by the activation state of mitogenic signaling pathways such as MAPK, AKT, CDK2, cAMP, and CK2 (Fig. 1). In addition, the availability of particular cofactors and their post-translational modification states are also determinants of PR gene selectivity (Hagan & Lange 2014). In short, PR is capable of inducing diverse biological outcomes dependent on the cellular context as determined by the presence or absence of activated signaling pathways and the availability of cofactors. Studies probing the complexity of PR action thus require particular care in both the design of model systems and the interpretation of specific results. For example, breast cancer cells in culture respond differently to progestins depending on the culture conditions. Cells cultured in 2D (adherent to plastic dishes) elicit a biphasic response characterized by one or few rounds of cell cycle progression followed by growth arrest (Musgrove *et al*. 1991, Groshong *et al*. 1997), whereas in 3D culture conditions (such as soft agar) progesterone is clearly mitogenic and a mediator of cell survival (Faivre & Lange 2007). These data may reflect an alteration in signaling pathways and kinase activation that is dependent upon cell polarity and/or cellular junctions or 'structural' communication that in turn informs PR gene selectivity and modulates the strength and duration of its transcriptional activity (i.e., aspects of PR action that are missed using reporter assays).

Notably, PR-A and PR-B are differentially susceptible to post-translational modifications in response to the same kinase signals. This complexity contributes to the distinctions between the genes they activate and ultimately the biological consequences for PR+ and nearby PR-null cells (i.e., responsive to PR-derived paracrine signals). For example, PR-B, but not PR-A, is robustly phosphorylated on Ser294 in response to MAPK activation.

http://jme.endocrinology-journals.org
DOI: 10.1530/JME-14-0252

Published by Bioscientifica Ltd.

Ser294 phosphorylation is a major regulatory input for PR-B, controlling increased sensitivity to progestin, an increased rate of ubiquitinylation of PR (an activation step for several steroid receptors (Salghetti *et al*. 2001)) required for degradation through the 26S proteasome pathway (Lange *et al*. 2000), decreased SUMOylation on K388 (Daniel *et al*. 2007), unliganded transcriptional activity (Daniel & Lange 2009), and altered promoter selectivity (Knutson *et al*. 2012*a*). Similarly, CUE domain containing 2 (CUEDC2), an ubiquitin-binding motif-containing protein, targets the K388 SUMOylation site for ubiquitinylation and degradation of PR, suggesting that PR ubiquitinylation may oppose SUMOylation via competition for the same required lysine residue (Zhang *et al*. 2007). In contrast, modest (low to unmeasurable in intact cells) PR-A Ser294 phosphorylation confers less responsiveness of this isoform to kinase inputs and increased K388 SUMOylation (a transcriptionally repressive modification) (Daniel *et al*. 2007). The increased SUMOylation of PR-A relative to PR-B may account for the increased trans-repressive activity of this isoform (Abdel-Hafiz *et al*. 2009). PR-A is known to repress the activities of PR-B, ER, androgen receptor (AR), and gonadotropin receptor (GR) (Abdel-Hafiz *et al*. 2002). PR isoforms also participate in distinct complexes with cofactors, owing in part to differences in post-translational modifications, and also due to cofactor-binding sites located in the PR-B N-terminus (Giangrande *et al*. 2000). Differential transcriptional complex components aid in determining relative transcriptional activities (i.e., altered hormone sensitivity) and are responsible for directing receptor gene selectivity; PR-A and PR-B have distinct and overlapping gene signatures in breast cancer cells (Richer *et al*. 2002). Importantly, evaluation of endogenous genes to determine the impact of phosphorylation events on steroid receptor action is critical. Phosphorylation events have been shown to alter promoter selection rather than absolute transcriptional activity. Luciferase assays measure transcriptional activity, but fail to detect alterations in promoter selectivity. Thus, mutant PRs that appear to be fully functional in luciferase assays repeatedly fail to activate selected endogenous (native) promoters of genes in intact cells (Qiu & Lange 2003, Daniel *et al*. 2009).

In breast cancer cell models and clinical studies, the ratio of PR-A to PR-B is a critical determinant of the biological or physiological response to progesterone (reviewed in Mote *et al*. (2007)). In normal tissues, PR-A and PR-B typically occur as a 1:1 ratio. However, unbalanced PR-A and PR-B expression occurs in the normal breast of women at high risk of developing breast cancer, while altered ratios in breast tumors are linked to endocrine resistance (Venkitaraman 2002, Mote *et al*. 2004). Differential signaling and transcriptional activities of the isoforms as well as altered ability of PR-A to trans-repress other steroid receptors probably contribute to breast pathologies (Abdel-Hafiz *et al*. 2002). The mechanisms that drive imbalanced PR-A-to-PR-B ratios are still under investigation. We hypothesize that increased kinase activity in the pre-malignant or early malignant setting drives PR-B phosphorylation leading to its hyperactivity and the subsequent rapid protein turnover (relative to PR-A) (Lange *et al*. 2000, Daniel *et al*. 2007). Thus, activated phospho-PR-B receptors exhibit an overall decreased steady-state protein level relative to PR-A receptors (which are not appreciably phosphorylated on Ser294 in response to MAPK or CDK2 activation). In this setting, PR-B exhibits heightened transcriptional activity on selected target genes, yet is less detectable. PR-B is widely recognized as the more proliferative isoform (Faivre & Lange 2007) and, as such, may primarily drive the dysplastic phenotypes observed in these tumors. In addition, loss of PR-A (the more repressive isoform) via promoter methylation (Pathiraja *et al*. 2011) may lead to loss of its protective actions and provide an epigenetic 'stepping stone' in tumor progression, an event that is similarly observed in endometrial tumors (discussed later in this review). Unfortunately, in the clinic, total PR levels are still measured using antibodies that fail to distinguish between PR isoforms (primarily conducted by immunohistochemistry (IHC)). This represents a missed opportunity to gain a much better understanding of PR isoforms as distinct biomarkers of disease progression. Given the differential activities of the receptors and their known effects on breast cancer cell biology, measuring the isoforms individually is likely to provide valuable information relevant to the use of tailored endocrine therapies. In addition, examining PR isoform-specific gene programs in tumors may further inform tumor biology and in turn drive treatment strategies targeting individual PR isoforms.

ER and PR crosstalk

An emerging paradigm in steroid receptor biochemistry is crosstalk between different receptor types, which allows receptors to modulate the signaling and transcriptional responses to non-cognate ligands. Recent studies have demonstrated that steroid receptors, including PR, ER, AR, and GR, participate in complexes with each other to a degree that is much more extensive than considered previously (Peters *et al*. 2009, Giulianelli *et al*. 2012,

http://jme.endocrinology-journals.org
DOI: 10.1530/JME-14-0252

Published by Bioscientifica Ltd.

Need *et al*. 2012, Daniel *et al*. 2014). This crosstalk is critical to understanding breast cancer biology because ER and PR are capable of modulating the activities of each other, which has implications for endocrine therapy responses. Our recent studies have demonstrated that ER, PR-B, and the coactivator and signaling scaffold molecule, PELP1, are constitutively complexed in human breast tumor samples and cell lines (Daniel *et al*. 2014). The consequences of this interaction in the presence of estrogen in ER+/PR+ breast cancer cell models include: enhanced ER phosphorylation, altered ER promoter selectivity, increased cellular proliferation, and decreased sensitivity to tamoxifen treatment (Daniel *et al*. 2014). In similar studies, ER and PR complexes exhibited enhanced transcriptional and proliferative responses to progestins as well (Giulianelli *et al*. 2012). Ultimately, these studies demonstrated that breast cancer cells harboring both ER and PR-B might, in fact, be exquisitely sensitive to exposure of either hormone. Perhaps, in the case of endocrine resistance, steroid receptors can substitute for each other or utilize alternative ligands to drive proliferative gene programs and escape inhibition of one receptor type. Relevant to this concept, ER-α may be activated by thyroid hormone (T_4) or by cholesterol metabolites (Tang *et al*. 2004, Wu *et al*. 2013), providing an easy 'escape' for tumors under the selection pressure of aromatase inhibitors.

PRs 'enable' signaling pathways via 'feed-forward' cofactor expression

Our recent studies have elucidated mechanisms by which PR acts as a sensor to integrate multiple signals (kinase pathway activation and hormone exposure) and ensure persistent activation of particular gene programs, in part via regulation of unique cofactor expression and by upregulation of signaling pathway components. For example, STAT5 is a PR target gene (Richer *et al*. 1998), and these factors interact directly and cooperate at numerous PR/STAT5 target genes (Hagan *et al*. 2013). Progesterone binding in the presence of high intracellular CK2 activity, a commonly activated kinase in cancer, initiates PR phosphorylation on Ser81 to induce robust STAT5 expression. PR then cooperates with STAT5 on selected target genes required for proliferation, stem cell maintenance, and inflammatory responses (Hagan *et al*. 2011*a*). In fact, we hypothesized that STAT5 functions as a pioneer factor recruiting S81 phosphorylated PR to specific chromatin loci (Hagan & Lange 2014). In other circumstances, namely during cell cycle progression through mitosis when both MAPK and CDK2 phosphorylation sites on PR are induced (Ser294, Ser345, and Ser400), cyclin D1 mRNA and protein are directly upregulated in response to progestin (Dressing *et al*. 2014). Phospho-S345 PR and cyclin D1 (acting as a coactivator of transcription) then cooperate as part of SP1-containing transcriptional complexes to enact a new genetic program in the cell, distinct from that of cells with little to no cyclin D1 expression (Dressing *et al*. 2014). This paradigm, whereby PR induces the same pathway factors that are required to fulfill specific context-dependent biological outcomes in response to progestin, is recapitulated in ovarian cells. In progesterone-treated ovarian cancer cell models, PR induces the increased expression of FOXO1, which in turn binds to PR in order to further modulate selected FOXO1/PR target genes required for progesterone-dependent induction of cellular senescence (Diep *et al*. 2013) (discussed later in this review). In addition, PRs are exquisitely sensitive to the local signaling environment in addition to ligand availability and the presence of cofactors that, when bound to PR, persistently direct or select highly specific genetic programs. The potential for distinct biological responses to transient vs persistent exposure to progestins is not considered clinically, for example, during HRT. The kinetics of feed-forward signaling events enacted by ligand-bound PRs is unknown and a topic for further study.

Uterus

Epidemiological role of progesterone in endometrial cancers

Continuous exposure to sex steroid imbalances, where there is insufficient progesterone or excessive estrogen acting upon endometrial tissue, can result in hyperplasia of the glandular epithelial tissue, with the potential to progress to atypical hyperplasia and endometrial carcinoma (Yang *et al*. 2011, Kim *et al*. 2013). Endometrial cancer is the most common gynecologic cancer and is classified into type I and type II carcinomas, each characterized by varied hormonal dependence, glandular/stromal architecture, progression, and patient outcome (Samarnthai *et al*. 2010). Type I endometrioid tumors represent 70–80% of all endometrial cancers, often estrogen dependent, presenting at a lower grade at an early stage with good patient prognosis. Type II non-endometrioid tumors are aggressive and rarely hormone dependent, diagnosed at a later stage with poorer prognosis and higher recurrence rates. In the progression

http://jme.endocrinology-journals.org
DOI: 10.1530/JME-14-0252

Published by Bioscientifica Ltd.

from low grade (well-differentiated cancers with clear glandular structures and stromal tissue) to high grade (poorly differentiated cancers), loss of stromal tissue and myometrial invasion is common. Owing to the ability of progesterone to antagonize proliferation and promote atrophy of the endometrium (Charles 1964), progesterone and its derivatives (progestins) have been used successfully as therapeutics to treat endometrial hyperplasias and cancers. High response rates (70–90%) are often observed for women with pre-invasive atypical hyperplasia or early stages of endometrial cancers without myometrial invasion (Kaku *et al*. 2001, Ushijima *et al*. 2007). Yet, the efficacy of progestins declines to modest response rates (15–25%) when used for cases of advanced or recurrent cancer (Banno *et al*. 2012) and more than 30% of patients with well-differentiated, hormone-dependent type I tumors will fail to respond (Shao 2013). The mechanisms that result in the progression from progestin sensitivity to the hormone refractory state, or 'progesterone resistance', are poorly understood.

Unlike most mammals, the uterine endometrium of human and some non-human primates undergoes cyclical monthly changes that result in the growth, angiogenesis, and differentiation of the functional (proliferative) endometrium (Ramsey *et al*. 1976, Clancy 2009). Shifts in the synthesis and secretion of the ovarian steroids, estrogen and progesterone, during this menstrual cycle serve as the principal hormonal drivers for these changes. Rising circulating estradiol during the mid- to late follicular phase of the cycle promotes the proliferation of the functional endometrium (Fig. 3); this most luminal portion of the endometrium regenerates each cycle from the basal endometrium and contains the glandular epithelial and stromal cells. Following ovulation, during the secretory luteal phase, rising circulating progesterone antagonizes these proliferative effects of estradiol and



Figure 3

Epithelial–stromal interactions regulating proliferation and differentiation of the uterine endometrium. The uterine endometrium is stylized in this figure, with predominant signaling pathways represented during the proliferative follicular phase of the menstrual cycle (above dotted line) and during the differentiation of the luteal phase (below dotted line). Arrows on the right indicate relative concentrations of circulating steroid hormone levels. During the follicular phase, the predominant steroid, estrogen (E_2; estradiol), acts through its receptor (ER; expressed in epithelium and stroma) to activate the PI3K/Akt pathway and promote inhibitory phosphorylation of GSK-3β, leading to activation of Wnt signaling, regulation of cell cycle proteins, and enhanced cell proliferation. E_2 can also induce the expression of critical growth factors such as Wnt ligands, IGF1, and FGFs that are secreted by the epithelia and stroma, and which bind to epithelial membrane receptors (i.e., receptor tyrosine kinases, RTKs) to support proliferation. During the luteal phase and early pregnancy, progesterone (P_4), as the predominant hormone, antagonizes E_2-induced proliferation and promotes differentiation of the glandular epithelium. P_4 acts through its receptor (PR) to induce expression of Indian hedgehog (IHH) within the epithelium, which binds to patched (PTCH) on the surface of the stromal cells and through the COUP-TFII and Hand2 complex inhibits expression of FGFs. In addition, P_4 also appears to induce the stromal expression of the Wnt signaling antagonist, dickkopf-related protein 1 (DKK1) and the transcription factor, FOXO1, which leads to inhibition of Wnt signaling, inhibition of cell cycle progression, and expression of decidualization-specific genes for stromal cell differentiation. Frequent alterations in endometrial cancer include altered ER/PR expression, *PTEN* loss of function, activation of PI3K/AKT signaling, and mutations to FGFR; these events are predicted to affect PR actions in the context of tumorigenesis.

http://jme.endocrinology-journals.org
DOI: 10.1530/JME-14-0252

Published by Bioscientifica Ltd.

supports the differentiation of stromal cells and the decidualization of the endometrium (Fig. 3).

Epithelial–stromal interactions within the endometrium: PR isoform specificity

PR-A and PR-B are expressed in both the epithelial and the stromal cells of the endometrium and their expression fluctuates during the menstrual cycle as well as during implantation and pregnancy. During the follicular phase of the cycle, both isoforms are expressed at high levels when the endometrium is proliferating, then decline after ovulation through the luteal phase (Mylonas *et al.* 2007). In general, PR-A expression appears to be predominant in the stromal cells, declining less during the luteal phase whereas, in glandular epithelial cells, PR-B dominance is observed in the late secretory phase (Mote *et al.* 1999). The antagonistic effects of progesterone on the estrogen-induced proliferation and growth of the functional endometrium occur primarily during the luteal phase and are dependent on the presence of functional PR expression. The absence of PR results in unopposed estrogen-induced endometrial hyperplasia in *Pr* knockout (PRKO) mice (Lydon *et al.* 1995). Tissue recombination studies with WT and PRKO uteri demonstrate that progesterone inhibits epithelial proliferation only in co-cultures with uteri expressing stromal PR (Kurita *et al.* 1998). Such studies support the importance of stromal PR expression as the inhibitory mediator of antiproliferative actions of progesterone. However, PR expression within the epithelia is still relevant as progesterone is unable to inhibit estradiol-induced endometrial proliferation or induce expression of important target genes encoding paracrine factors or cell cycle regulatory proteins in mice uteri lacking epithelial-specific PR expression (Franco *et al.* 2012). Therefore, the interplay between the epithelial and stromal cells of the endometrium is essential, with both cell types playing a role in the actions of progesterone.

Similar to the breast (discussed earlier in this review), each PR isoform can have very distinct target genes and biological functions, dependent on hormonal milieu and cellular context. In general, PR-B is considered as the stronger transcriptional activator and PR-A functions as a transcriptional inhibitor of PR-B activity (Tora *et al.* 1988, Vegeto *et al.* 1993, Hovland *et al.* 1998). Selective ablation of PR-A in mice results in a PR-B-dependent gain of function, with enhanced estradiol-induced endometrial proliferation (Mulac-Jericevic *et al.* 2000, Conneely *et al.* 2003). This unexpected observation suggests that PR-A is probably necessary for opposing the actions of both estradiol and progesterone in the endometrium, thereby limiting the proliferative effects of the PR-B receptor in this tissue. In addition, PR-A is also needed for progesterone-mediated changes during the luteal phase and implantation of the conceptus, as lack of PR-A results in impaired uterine implantation and little decidualization of the endometrial layer. This delicate balance of PR isoforms is further illustrated with transgenic mice overexpressing PR-A in glandular epithelium and stromal tissue. This experimental increase in the PR-A:PR-B ratio results in endometrial hyperplasia and atypia with enhanced expression of uterine epithelial growth factors such as amphiregulin known to be regulated by progesterone; these effects can be abolished by treatment with the antiprogestin, mifepristone (Fleisch *et al.* 2009). These results indicate that progesterone can be either an anti- or pro-proliferative force on the endometrium depending on isoform expression.

Studies on the uterine myometrium highlight the fact that the ratio of PR isoforms may be naturally exploited to remove the inhibitory effects of progesterone on myometrial contractions, thus allowing for estrogen activation and the initiation of parturition. One mechanism for this functional progesterone withdrawal may be a shift in the PR-A:PR-B ratio expressed within the myometrium with a concomitant antagonism of PR-B-mediated transcription (Pieber *et al.* 2001, Mesiano *et al.* 2002, 2011, Merlino *et al.* 2007). There is also evidence that a change in the PR-A:PR-B:PR-C isoform expression, specifically within the fundal myometrium (i.e., upper portion of the uterine body), could contribute to this process. Protein and mRNA expression of PR-C, as well as PR-B, increase during labor in women and are associated with NFκB activation and cytokine-mediated transcriptional activation of the PR gene (Condon *et al.* 2006). The potential transcriptional consequences of such isoform shifts, as experimentally manipulated or observed in these studies, are evident in gene array studies with primary human stromal cells expressing exogenous PR-A, PR-B, or the combination, where distinct expression profiles are observed for each isoform as well as progesterone concentration-dependent efficacy that was both target gene and isoform specific (Yudt *et al.* 2006). Overall, these results indicate that progesterone can be a positive or negative driver of cell processes such as endometrial proliferation or myometrial contractions depending on the isoform expression and downstream transcriptional and signaling activation. Misregulation of isoform expression, therefore, can lead to dysfunction and pre-neoplastic events.

http://jme.endocrinology-journals.org
DOI: 10.1530/JME-14-0252

Published by Bioscientifica Ltd.

Epithelial–stromal interactions within the endometrium: PR-driven paracrine communication

The regulation of paracrine factors and their signaling pathways by progesterone supports epithelial–stromal communication, which is critical for normal uterine function and may play a role in endometrial cancer pathogenesis (Fig. 3). Signaling via factors such as Indian hedgehog (*Ihh*) and *Wnt* ligands can be modulated by progesterone through regulation of the expression or activity of these paracrine factors or their downstream signaling molecules (Wetendorf & DeMayo 2012; Fig. 3). Within the hedgehog pathway, *Ihh* and dickkopf-related protein 1 (*Dkk1*) are PR target genes (Takamoto *et al*. 2002). Activation of stromal PR results in induction of *Ihh* expression by the epithelia and the subsequent stromal expression of patched homolog 1 (*Ptch1*) and nuclear receptor subfamily 2, group F, member 2 (*Nr2f2*) (Fig. 3). This can lead, in particular through NR2F2 (e.g., COUP-TFII), to activation of transcription factors such as *Hand2* and potential antagonism of mitogenic pathway activation by growth factors, such as fibroblast growth factors (FGFs) (Li *et al*. 2011). This paracrine loop is thought to inhibit estrogen signaling and thereby halt uterine epithelial proliferation. The Wnt/β-catenin signaling pathway is critical for the control of stem cell/progenitor compartments and the balance between 'stemness' (e.g., proliferation with Wnt pathway active) and differentiation (e.g., inhibited Wnt pathway) in many tissues (Clevers 2006). In the endometrium, this pathway is also implicated in control of the proliferation–differentiation shift during the menstrual cycle and the actions of progesterone during the luteal phase may be through the inhibition of this pathway (Wang *et al*. 2010). Exposure to estrogen during the proliferative phase of the cycle leads to activation of this pathway with enhanced expression of Wnt pathway components (i.e., *WNT4*, *WNT5A*, *FZD2* (Hou *et al*. 2004)) and Wnt target genes such as *IGF1* (Wang *et al*. 2009), a critical endometrial growth factor secreted by stromal cells (Cooke *et al*. 1997, McCampbell *et al*. 2006), as well as downregulation of DKK1 (stromal) and FOXO1, Wnt/β-catenin signaling inhibitors (Talbi *et al*. 2006, Wang *et al*. 2009; Fig. 3). Notably, Wnt4 is a paracrine effector for progesterone-induced expansion of the mammary stem cells (Joshi *et al*. 2010). Crosstalk with the PI3K/Akt pathway is also involved as E2-induced Akt activation, via ERα, results in inhibition of glycogen synthase kinase (GSK-3β) and stabilization of β-catenin with enhanced transcription of Wnt target genes, ultimately leading to cell cycle progression (Tong & Pollard 1999). Progesterone antagonizes the Wnt/β-catenin pathway via enhanced transcription of *DKK1* and *FOXO1* genes, retention of active GSK-3β, and nuclear exclusion of cyclin D1 resulting in cell cycle arrest (Chen *et al*. 2005, Ward *et al*. 2008, Wang *et al*. 2009, Kyo *et al*. 2011). Interestingly, blocking FOXO1 expression attenuates the ability of progesterone to inhibit epithelial cell growth, whereas expression of a dominant negative AKT enhances the inhibitory effect of this hormone (Kyo *et al*. 2011). These studies emphasize the crosstalk between paracrine signaling and mitogenic pathways modulated by ER and PR in the homeostasis of endometrial growth. Notably, the dysregulation of the PI3K/Akt and Wnt/β-catenin, in particular, is one hallmark of endometrial cancer pathogenesis. It is tempting to speculate that early events such as activating mutations in these key signaling pathways lead to imbalanced hormone-dependent stromal and epithelial crosstalk that then predisposes to neoplastic transformation of endometrial tissue.

Mechanisms of progestin resistance in endometrial cancer

Misregulation of PR isoform expression, localization, and activity are common phenotypes observed in EC that could be involved and potentially targeted to improve sensitivity to progestin therapy. In general, hyperplasias express higher levels of PR-A and PR-B (Miyamoto *et al*. 2004) and comparison of low- to high-grade endometrial cancers reveals reduced to absent expression of one or both isoforms in epithelia or stroma; these expression profiles are often associated with shorter progression-free survival and overall survival rates (Leslie *et al*. 1997, Miyamoto *et al*. 2004, Sakaguchi *et al*. 2004, Shabani *et al*. 2007, Jongen *et al*. 2009, Kreizman-Shefer *et al*. 2014). This silencing of PR expression may be due to hypermethylation of CpG islands within the promoter or first exon regions of the *PR* gene or due to the presence of associated deacetylated histones. These epigenetic modifications were observed in endometrial cancer cell lines as well as tumor samples and may be exclusive to PR-B (Sasaki *et al*. 2001, Xiong *et al*. 2005, Ren *et al*. 2007). Treatment of such cells with DNA methyltransferase or histone deacetylase inhibitors can restore both PR-B expression and its regulation of target genes such as *FOXO1*, *p21* (CDKN1A), *p27* (*CDKN1B*), and *cyclin D1 (CCND1)* (Xiong *et al*. 2005, Yang *et al*. 2014). Downregulation of PR via post-transcriptional mechanisms such as miRs could be another means of suppressing progesterone sensitivity, as observed in breast cancer cell

http://jme.endocrinology-journals.org
DOI: 10.1530/JME-14-0252

Published by Bioscientifica Ltd.

lines via overexpression of miR-26a and miR-181a (Maillot *et al*. 2009), but this remains to be examined in endometrial cancer models.

Post-translational modifications of PR, such as phosphorylation or SUMOylation, serve as input points for activated mitogenic pathways to regulate PR signaling (Dressing *et al*. 2009, Hagan *et al*. 2011*b*) and, therefore, may contribute to progesterone resistance. Studies with endometrial stromal cells have demonstrated that activation of cAMP signaling can sensitize cells to progesterone by suppressing SUMOylation of the PR-A isoform leading to enhanced transcriptional activity and target gene induction, supporting normal endometrial decidualization (Jones *et al*. 2006). Although the relevance of such PR modifications has not been extensively explored in the context of endometrial cancer, it is known that oncogenic activation of KRAS, PI3K, or AKT and/or loss of functional tumor suppressors such as PTEN are common genetic alterations observed in endometrial cancer (Hecht & Mutter 2006; Fig. 1). Janzen *et al*. (2013) have recently used an *in vivo* endometrial regeneration model to test how these common genetic alterations affect PR isoform expression and responsiveness to progestin therapy within epithelial and stromal compartments of the endometrium. Tumors generated from epithelial cells lacking *PTEN* were responsive to progesterone showing early decreased proliferation and later apoptosis, but co-administration of estrogen was necessary for tumor resolution as well as maintenance of stromal PR expression. Deletion of *PR* in stromal cells or combined epithelial-specific genetic mutations (i.e., *PTEN* loss and Kras activation) caused progesterone resistance, while overexpression of PR in stroma was able to resensitize tumors to therapy. Interestingly, tumors with the combined mutations showed depressed PR expression, especially stromal PR-A, due to epigenetic modifications; analysis of the PR-A promoter revealed multiple sites of hypermethylation. In addition to the function of stromal PR-A, studies have also highlighted the importance of PR-B where DNA methylation and decreased PR-B expression in endometrial cancer result in decreased FOXO1 and BIRC3 expression, enhancement of adhesion molecules, and cell cycle regulatory proteins. This ultimately lifts progesterone antagonism of estrogenic effects resulting in enhanced cell proliferation and survival (Shao 2013). These studies illustrate the importance of functional PR expression, uterine epithelial/tumor–stromal interactions, and hormonal milieu on PR signaling and therapeutic efficacy.

Ovary

Epidemiological role of progesterone in ovarian tumors

Ovarian cancer is the seventh most common cause of cancer-related deaths worldwide (Jemal *et al*. 2011). As the deadliest of all gynecologic malignancies, ovarian cancer has a death rate of more than 50% due to late detection and diagnosis of the disease and intrinsic or acquired resistance to current therapeutic regimens. The identification of robust biomarkers for early detection will have a substantial impact on survival rates, while prognostic molecular markers may allow for efficacious targeted therapeutic strategies.

A considerable body of epidemiological data suggests that progesterone and progestins play a protective role against ovarian carcinogenesis. Progesterone deficiencies due to increasing age, infertility, or a genetic LOH at the *PR* gene locus are associated with an increased risk of ovarian cancer (Gabra *et al*. 1996, Edmondson & Monaghan 2001). In contrast, elevated progesterone levels decrease the risk of ovarian cancer. The protective effect of pregnancy has been documented in Asian, European, and North American populations (Banks *et al*. 1997); progesterone levels during pregnancy are tenfold greater than luteal phase levels measured during the menstrual cycle. Similarly, hormonal oral contraceptive use has been consistently associated with a reduced risk. In an analysis of 20 epidemiological studies between 1970 and 1991, it was estimated that a 35% reduction in the risk was associated with ever-use of oral contraceptives (Hankinson *et al*. 1992). Additionally, the risk of ovarian cancer is correlated with the duration of oral contraceptive use: 10–12% decrease in the risk with 1 year of use and 50% decrease after 5 years of use in both nulliparous and parous women (Hankinson *et al*. 1992). Progesterone exerts a protective effect on the risk of ovarian cancer by reducing ovulation through elevated progesterone levels from oral contraceptive use or during pregnancy. Furthermore, PR expression, PR-B specifically (Akahira *et al*. 2000, 2002, Lenhard *et al*. 2012), in ovarian tumors is a favorable prognostic marker associated with longer progression-free survival (Hempling *et al*. 1998, Akahira *et al*. 2000, Munstedt *et al*. 2000, Lindgren *et al*. 2001, Lee *et al*. 2005, Hogdall *et al*. 2007, Tangjitgamol *et al*. 2009, Yang *et al*. 2009, Sinn *et al*. 2011).

BRCA1/2 mutations may alter the production and sensitivity to estrogen and progesterone as carriers have an increased risk for breast and ovarian cancer. Studies on mice carrying a *Brca1* mutation in ovarian granulosa

http://jme.endocrinology-journals.org
DOI: 10.1530/JME-14-0252

Published by Bioscientifica Ltd.

(i.e., hormone-producing) cells (Chodankar *et al*. 2005, Hong *et al*. 2010, Yen *et al*. 2012) and humans with either a *BRCA1* or *BRCA2* mutation (Widschwendter *et al*. 2013) demonstrated that *BRCA* mutations confers higher serum (circulating) levels of both estrogen and progesterone. Moreover, serous tubal intra-epithelial carcinoma in the distal end of the fallopian tube was discovered in 10–15% of *BRCA* carriers who had prophylactic salpingo-oophorectomy (Folkins *et al*. 2008, Norquist *et al*. 2010). Ultimately, little mechanistic information exists related to the impact that hormones have on the prevention and/or pathogenesis of ovarian cancer. The evidence related to the pathophysiology of ovarian cancer suggests a strong connection with estrogen, progesterone, and, more recently, androgen actions in the development and progression of ovarian cancer. Steroid hormone action in ovarian cancer is grossly understudied, and there is an urgent need to focus on the early events related to the contribution of hormones in the context of altered signaling events (loss of *p53* (*TP53*) or *PTEN*, elevation of AKT signaling) that predispose women, including those with *BRCA* mutations, to an increased risk of breast and ovarian cancer.

PR as a prognostic marker in ovarian tumors

Recent studies have revealed that 'ovarian cancer' is not a single disease, and a significant portion of ovarian tumors may not originate from ovarian tissue. At present, five major histopathological subtypes of epithelial ovarian cancer have been characterized and are phenotypically and molecularly distinct: high-grade serous, low-grade serous, endometrioid, clear cell, and mucinous. Pathological and genomic studies indicate that cancers of these major subtypes are frequently derived from non-ovarian tissues that have metastasized and homed to the ovary (Fig. 4). Clear cell and endometrioid ovarian cancers are derived either from the cervix or from endometriosis, which itself is associated with retrograde menstruation from the endometrium (Obata *et al*. 1998, Sato *et al*. 2000; Fig. 4). Invasive mucinous ovarian cancers are metastases from the lower intestinal tract (e.g., stomach, colon, and appendix) to the ovary (Khunamornpong *et al*. 2006; Fig. 4). High-grade serous ovarian cancers are derived from the distal fallopian tubes (Lee *et al*. 2007, Folkins *et al*. 2008; Fig. 4). A recent study has demonstrated that ovulation, the release of hormones (e.g., estrogen and progesterone), growth factors, and inflammatory factors among others, promoted the migration of intrauterine-injected malignant cells toward the ovarian stromal compartment to form 'ovarian' tumors (Yang-Hartwich *et al*. 2014). Thus, it is plausible that the unique hormonal milieu provided by functional ovaries serves to attract pre-malignant and malignant cells that may remain dormant (i.e., under progesterone concentrations) or fully progress to tumors (i.e., post-menopausal contexts or upon loss of progesterone or functional PRs). Approximately 90% of ovarian cancers are detected in the ovary, with over 50% ovarian cancers diagnosed in post-menopausal women (American Cancer Society, 2014. Cancer Facts and Figures 2014. Atlanta).

Until recently, little has been known about the relative distribution of PR within the subtypes of epithelial ovarian tumors. In a cohort of 504 tumors, we reported that 35% of ovarian tumors are PR positive, with the highest total PR expression in endometrioid (67%) and serous (35%; low-grade serous, 64%) subtypes (Diep *et al*. 2013). In accordance with our study, the international Ovarian Tumor Tissue Analysis consortium examined the association of ER and PR expression with subtype-specific survival in ~3000 invasive epithelial ovarian tumors reporting positive total PR expression in endometrioid (67%), low-grade serous (57%), and high-grade serous (31%) tumors (Sieh *et al*. 2013). Additionally, the study confirmed the prognostic significance of PR expression in ovarian tumors strongly expressing PR ($\geq$50% tumor cell nuclei staining). Strong PR expression in high-grade serous ovarian carcinomas was associated with a significant improvement in survival; positive PR expression (weak or strong) in endometrioid carcinomas was associated with significantly improved disease-specific survival independent of patient age and tumor grade, site, and stage. Notably, ER expression conferred a patient survival advantage in endometrioid ovarian tumors only. ER may contribute to the favorable prognosis in endometrioid ovarian tumors via regulation of PR expression; a functional ER signaling pathway promotes robust PR expression. While total PR levels are routinely measured in breast and endometrial cancers (but rarely in ovarian cancer) for clinical management and disease treatment, very few studies have examined the levels of PR isoforms in ovarian tumors. To our knowledge, only three studies (Akahira *et al*. 2000, 2002, Lenhard *et al*. 2012) have reported differential expression of PR isoforms in ovarian tumors. These studies have reported a dominance of PR-B expression in ovarian tumors across all sub-types, with PR-B frequently expressed in the serous subtype. In contrast, PR-A expression was weakly expressed in mucinous and serous ovarian carcinomas and comparison of normal ovarian tissues with malignant ovarian tissues

http://jme.endocrinology-journals.org
DOI: 10.1530/JME-14-0252

Published by Bioscientifica Ltd.



Histopathological subtype	Sites of origin
Clear cell	cervix, endometrium (retrograde menstruation)
Endometrioid	
Mucinous (invasive)	lower intestinal tract (colon, appendix), stomach
Serous (high-grade)	fallopian tubes

Figure 4

Cellular origins of ovarian cancer. Ovarian cancer is a collective term for several distinct invasive diseases that originate in the peritoneal cavity. *Inset*, the known sites of origin associated with the major histopathological subtypes of ovarian cancer. Mucinous ovarian cancers are metastases on the ovary from the gastrointestinal tract, including the stomach, colon, or appendix. Endometrioid and clear cell ovarian cancers are derived either from the cervix or from the uterus via progression of endometriosis, which is linked to retrograde menstruation from the endometrium. High-grade serous ovarian cancers are either derived from metastases from the distal fallopian tube or from the surface of the ovary.

revealed reduced to absent expression in malignant tumors relative to PR-B (Akahira *et al*. 2002).

Progesterone actions in ovarian cancer

The molecular mechanisms of progesterone's protective role in ovarian cancer are not well understood; both proliferative and inhibitory actions of progesterone have been reported in ovarian cancer cell line models. Several independent *in vitro* studies demonstrated antiproliferative actions of progesterone at higher concentrations ($\geq$1 μM) in ovarian cancer cells, primarily through the induction of apoptosis (Bu *et al*. 1997, Keith Bechtel & Bonavida 2001, Yu *et al*. 2001, Syed & Ho 2003), while fewer studies reported progesterone as proliferative in these cells at lower concentrations (Syed *et al*. 2001, Fauvet *et al*. 2006). The opposing cellular responses of ovarian cancer cells to progesterone may be attributed to cell context-dependent regulatory inputs to PR (discussed earlier in this review), such as progesterone dosing, kinase activation state of the cells, cofactor availability, or PR-A and PR-B ratios. Ovarian cancer cells are susceptible to concentration-dependent and biphasic effects within the same cell model systems as mentioned previously for uterine and breast (in 2D culture systems) cancer cells. Similar to breast and uterus, crosstalk between PR and growth factor-mediated signaling pathways (i.e., protein kinases) presumably directs PR promoter selection and specific cell fates (e.g., apoptosis). The relative abundance of cofactors that associate with PR also varies in a tissue-specific manner (Giangrande *et al*. 2000, Han *et al*. 2005). As in other tissues (discussed earlier in this review), shifts in PR isoform ratios (PR-A and PR-B) and cofactor availability may contribute to variations in biological responses to progesterone.

http://jme.endocrinology-journals.org
DOI: 10.1530/JME-14-0252

Published by Bioscientifica Ltd.

PR isoform-specific actions are largely undefined in ovarian cancer. However, our recent study has defined a mechanism for PR-B regulation of ovarian cancer cellular senescence in response to progesterone. Using ovarian cancer cell models, we demonstrated that ligand-activated PR-B acting through a FOXO1-dependent mechanism induced p21, a known mediator of cellular senescence. FOXO1, a transcriptional factor, has been demonstrated to interact physically with other nuclear steroid hormone receptor proteins, such as AR (Li *et al*. 2003, Fan *et al*. 2007), ER-α (Schuur *et al*. 2001), and both PR isoforms (Kim *et al*. 2005, Rudd *et al*. 2007). Our study demonstrated that PR-B and FOXO1 were co-recruited to a PRE-containing region in the upstream promoter of p21 upon progestin (R5020) treatment. Both proteins were required to cooperatively activate progestin-induced p21 expression and induce PR-dependent cellular senescence. PR-B appears to be a more potent driver of ovarian cancer cell senescence relative to PR-A; PR-B but not PR-A induces robust FOXO1 expression (Diep CH, Knutson TP, and Lange CA, unpublished observations). As stated above for breast studies, we suspect that PR isoforms in ovarian cancer models are also exquisitely sensitive to kinase inputs that may alter this biological outcome. Both PR-B and FOXO1 are tightly regulated by phosphorylation events. Hormone-driven breast and gynecological cancers frequently exhibit upregulated protein kinases, such as MAPK (Faivre *et al*. 2005), CDK2 (Pierson-Mullany & Lange 2004), and CK2 (Hagan *et al*. 2011*a*), which directly phosphorylate and modulate PR-B target gene selectivity (Fig. 1). Notably, the same kinases that are recruited to PR-B in 'rapid' signaling (i.e., extranuclear) complexes (i.e., CDK2 and MAPK) also inhibit FOXO1 via regulation of specific phosphorylation sites that favor nuclear export (Hedrick *et al*. 2012). Dysregulation of FOXO1 is associated with tumorigenesis and cancer progression. FOXO1 is downregulated in several carcinomas, including ovarian cancer (Goto *et al*. 2008), through alterations in upstream regulators, post-translational dysregulation, or by genetic mutations (Myatt & Lam 2007). Specifically, AKT-mediated serine/-threonine phospho-regulation of FOXO1 is well defined and prevents FOXO1 nuclear accumulation, thus impairing target gene regulation (Myatt & Lam 2007). As mutations of *PI3K*s or *PTEN* are common early events in cancer (particularly in breast, uterine, and ovarian cancers), activated AKT and other mitogenic protein kinases may prevent PR-induced senescence signaling by nuclear exclusion of FOXO1. Thus, the early loss or inactivation of FOXO1 may render PR 'incompetent' at genes required for the induction of cellular senescence, leading to the loss of protective 'sensing' by progesterone in ovarian tumors. Whether these events may redirect PR to 'alternate' genes that instead favor tumor progression is unknown and a topic for further study.

Finally, mortality rates for ovarian cancer have remained largely unaffected despite clinical advances in detection methods, surgical techniques, and treatment regimens. Although extensive surgery followed by chemotherapy is often effective at inducing clinical remission, the treatment is toxic and rarely results in a cure. Other treatment regimens, such as hormonal therapy, have been evaluated for ovarian cancer. The use of progestins alone (megestrol acetate and medroxyprogesterone acetate) as ovarian cancer therapies has been examined in several relatively small phase II clinical trials with variable inclusion criteria and modest response rates (Modugno *et al*. 2012). However, retrospective studies evaluating the association of total PR expression and progression-free disease survival (Hempling *et al*. 1998, Akahira *et al*. 2000, Munstedt *et al*. 2000, Lindgren *et al*. 2001, Lee *et al*. 2005, Hogdall *et al*. 2007, Tangjitgamol *et al*. 2009, Yang *et al*. 2009, Sinn *et al*. 2011, Sieh *et al*. 2013) support the concept that subsets of PR-positive ovarian tumors are highly sensitive to hormones and thus more likely to respond to endocrine therapy.

Overall, identifying the mechanisms governing PR-A- vs PR-B-specific gene regulation may provide insight for exploiting the protective actions of progesterone in PR-positive gynecological tumors to induce growth arrest and ultimately favor cell death, namely the development of PR isoform-specific ligands may allow for promotion of PR-B-driven cellular senescence in ovarian cancer or induction of the protective actions of PR-A in uterine cancer. Growth-arrested senescent cells cannot further divide, but depend upon specific kinase-mediated signal transduction pathways for prolonged survival, and thus may be more vulnerable to subsequent therapies that inhibit mitogenic protein kinases and thereby promote apoptosis. Thus, as part of novel combination therapies, PR-targeted strategies could provide a safe and useful means to improve treatment outcomes and increase overall patient survival.

Antiprogestins in preclinical and clinical development

Table 1 depicts antiprogestins currently under preclinical and clinical development in breast cancer, endometrial cancer, endometriosis, leiomyomas, and ovarian cancer. Mifepristone (RU486) has been studied in several phases I

http://jme.endocrinology-journals.org
DOI: 10.1530/JME-14-0252

Published by Bioscientifica Ltd.

Table 1 Current antiprogestins in preclinical and clinical development in breast and gynecological diseases

Antiprogestin	Phase	Disease	References
APR19	Preclinical	Breast cancer	Khan *et al*. (2013)
EC304	Preclinical	Breast cancer	Nickisch *et al*. (2013)
ORG31710	Preclinical	Breast cancer	Bakker *et al*. (1990)
WAY-255348	Preclinical	Breast cancer	Yudt *et al*. (2011)
Asoprisnil (J867)	II	Endometriosis	DeManno *et al*. (2003) and Chwalisz *et al*. (2007)
	II	Leiomyoma	
Lonaprisan (BAY86-5044, ZK230211)	II	Breast cancer	Jonat *et al*. (2013)
Mifepristone (RU486)	I–II	Breast cancer	Romieu *et al*. (1987), Klijn *et al*. (1989) and Perrault *et al*. (1996)
	II	Endometrial cancer	Ramondetta *et al*. (2009)
	I–III	Leiomyoma	Engman *et al*. (2009) and Yerushalmi *et al*. (2014)
	II	Ovarian cancer	Rocereto *et al*. (2000) and Rocereto *et al*. (2010)
Onapristone (ZK98299)	II	Breast cancer	Helle *et al*. (1998) and Robertson *et al*. (1999)
	I	PR+ tumors	
Telapristone (CDB-4124, Proellex)	II	Breast cancer	Gupta *et al*. (2013)
	II	Endometriosis	Ioffe *et al*. (2009)
Ulipristal (CDB-2914)	II–III	Leiomyoma	Levens *et al*. (2008)

and II clinical trials for breast and gynecological diseases and cancers as it blocks the transcriptional activity of PR by directly binding to and recruiting corepressors to PR (depending on cellular context) (Han *et al*. 2007). Paradoxically, mifepristone was originally developed as a potent antiglucocorticoid compound and was later discovered to have antiprogesterone activity when mifepristone caused termination of pregnancy in preclinical studies (Spitz & Bardin 1993). Similarly, mifepristone can also bind to the AR (Song *et al*. 2004). While the structures of progesterone, glucocorticoid, and ARs are very similar, the varying affinity of mifepristone to these steroid receptors may account for the limited efficacy and substantial toxicity observed in several clinical trials for breast and ovarian cancer (Perrault *et al*. 1996, Rocereto *et al*. 2010). A new generation of PR antagonists attenuates malignant proliferation of tumors and is highly selective for PR with potent antiprogesterone activity but minimal antiglucocorticoid effects in *in vitro* and *in vivo* studies. These PR antagonists include APR19, CDB-2914 (ulipristal), CDB-4124 (telapristone), J867 (asoprisnil), ORG31710, WAY-255348, ZK230211 (lonaprisan), ZK98299 (onapristone), and a 17-fluorinated steroid branded as EC304 (Table 1) (reviewed in Chabbert-Buffet *et al*. (2005), Spitz (2006), Knutson & Lange (2014) and Goyeneche & Telleria (2015)). Ultimately, the development of highly selective PR antagonists, and the identification of patient cohorts that will benefit from antiprogestins and their use in combination with other endocrine therapies may significantly advance hormone-modulation strategies for breast and gynecological cancers.

Summary of discussion

Herein, we have discussed the pivotal role of altered progesterone signaling in the development and progression of hormone-regulated tumors. In the breast, progesterone promotes a proliferative and pro-survival response (i.e., PR is a major downstream effector of estrogen signaling), but inhibits estrogen-induced growth in the reproductive tract. The paradoxical effects of progesterone observed in tumors arising from these tissues may be largely dependent on endogenous cell context and the tissue

Table 2 Summary of PR isoform actions

Tissue type	Isoforms	Isoform-specific actions of progesterone
Breast	PR-A	Trans-represses PR, ER, AR, and GR activities Weaker transcriptional activator relative to PR-B
	PR-B	Required for normal mammary gland development and expansion Proliferative isoform in breast tumors
Uterus	PR-A	Required for normal uterine development and function Dominant isoform in normal stromal cells Anti-proliferative actions
	PR-B	Dominant isoform in normal glandular epithelial cells Proliferative isoform in endometrial cancer cells
Ovary	PR-A	Essential for normal ovarian function Reduced or absent expression in ovarian carcinomas
	PR-B	Dominant isoform in ovarian carcinomas Anti-proliferative actions (e.g., senescence and apoptosis)

http://jme.endocrinology-journals.org
DOI: 10.1530/JME-14-0252

Published by Bioscientifica Ltd.

microenvironment, namely the opposing effects of progesterone may be attributed to altered expression or activity of PR isoforms, the contextual interactions between the epithelial and stromal compartments observed in breast and endometrial tissues, changes in their relative regulation either by post-translational modifications or via differential crosstalk with cofactor-binding partners that serve as major inputs to altered transcriptional activity and promoter selection in the various target tissues (see Table 2 for an overview).

Although elegant models have recently emerged (Karst *et al*. 2011, Tanos *et al*. 2013), knowledge gaps still exist. What are the best methods and experimental models to elucidate progesterone-specific effects in hormone-responsive tumors? While breast, endometrial, and ovarian cancers are diagnosed in both pre- and post-menopausal populations, a majority of the current cell-based models were originally established from post-menopausal patients. To understand steroid receptor actions, cells are treated with varying concentrations of exogenous hormones that may or may not reflect true physiological levels experienced in a pre-menopausal (cyclical hormone exposure) or post-menopausal (constant/low hormone exposure) context. Are the hormone concentrations used in the laboratory relevant to these contexts and thus to the biology of the tumors that arise? In addition, decreased PR expression is associated with progression of disease in breast and gynecologic cancers (Gross *et al*. 1984, Balleine *et al*. 1999), whereas over 50% of acquired endocrine-resistant breast tumors retain PR expression (Encarnacion *et al*. 1993, Johnston *et al*. 1995). How do breast and other tumors lose PR expression and/or regain it during extended periods of endocrine (antiestrogen therapy)? How should we model these changes? Concerning *in vitro* models, PR expression is often lost when primary isolates or immortalized cell lines are continuously cultured on 2D surfaces. The development of co-culture or 3D models may more accurately reflect *in vivo* cellular architecture relevant to paracrine signaling and tumor biology (Lo *et al*. 2012) and will allow a more accurate characterization of the mechanisms and biological effects of hormone and antitumor treatments. Finally, routine detection and quantification of individual PR isoforms in clinical samples may provide valuable information as potentially distinct biomarkers of tumor behavior that could be used to further guide endocrine therapy.

Understanding how PRs function differentially in each normal and neoplastic tissue type will reveal how these highly modified receptors can be therapeutically targeted, perhaps as separate isoforms, to favor one biological outcome (growth inhibition, senescence, and apoptosis) over another (proliferation and survival). Ultimately, in order to effectively manipulate PR action pharmacologically to treat tumors arising from different tissue types, we must first appreciate their mechanistic complexity. Isoform-specific ligands as activators or inhibitors would be a valuable set of tools to accomplish this goal. In the current age of cancer genomics and personalized medicine, clinical readouts of PR-driven gene signatures may provide an additional means to discern context-dependent protective vs deleterious PR actions present in individual tissues and tumors.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Funding

This work was supported by NIH grant R01 CA159712 (to C A L), a supplement to the parent NIH grant R01 CA15972-S1 (to C A L), Cancer Biology Training Grant NIH T32 CA009138 (to C H D) and National Center for Advancing Translational Sciences of the National Institutes of Health Award UL1TR000114 (to C H D).

References

Abdel-Hafiz H, Takimoto GS, Tung L & Horwitz KB 2002 The inhibitory function in human progesterone receptor N termini binds SUMO-1 protein to regulate autoinhibition and transrepression. *Journal of Biological Chemistry* **277** 33950–33956. (doi:10.1074/jbc.M204573200)

Abdel-Hafiz H, Dudevoir ML & Horwitz KB 2009 Mechanisms underlying the control of progesterone receptor transcriptional activity by SUMOylation. *Journal of Biological Chemistry* **284** 9099–9108. (doi:10.1074/jbc.M805226200)

Akahira J, Inoue T, Suzuki T, Ito K, Konno R, Sato S, Moriya T, Okamura K, Yajima A & Sasano H 2000 Progesterone receptor isoforms A and B in human epithelial ovarian carcinoma: immunohistochemical and RT-PCR studies. *British Journal of Cancer* **83** 1488–1494. (doi:10.1054/bjoc.2000.1463)

Akahira J, Suzuki T, Ito K, Kaneko C, Darnel AD, Moriya T, Okamura K, Yaegashi N & Sasano H 2002 Differential expression of progesterone receptor isoforms A and B in the normal ovary, and in benign, borderline, and malignant ovarian tumors. *Japanese Journal of Cancer Research* **93** 807–815. (doi:10.1111/j.1349-7006.2002.tb01323.x)

American Cancer Society 2014 *Cancer Facts and Figures*. Atlanta GA: American Cancer Society.

Asselin-Labat ML, Shackleton M, Stingl J, Vaillant F, Forrest NC, Eaves CJ, Visvader JE & Lindeman GJ 2006 Steroid hormone receptor status of mouse mammary stem cells. *Journal of the National Cancer Institute* **98** 1011–1014. (doi:10.1093/jnci/djj267)

Bakker GH, Setyono-Han B, Deckers GH & Klijn JGM 1990 Treatment of experimental breast cancer with new antiprogestins (ORG31710, ORG31806). *European Journal of Cancer & Clinical Oncology* **26** 172.

Balleine RL, Earl MJ, Greenberg ML & Clarke CL 1999 Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women. *British Journal of Cancer* **79** 1564–1571. (doi:10.1038/sj.bjc.6690249)

http://jme.endocrinology-journals.org
DOI: 10.1530/JME-14-0252

Published by Bioscientifica Ltd.

Banks E, Beral V & Reeves G 1997 The epidemiology of epithelial ovarian cancer: a review. *International Journal of Gynecological Cancer* **7** 425–438. (doi:10.1046/j.1525-1438.1997.09756.x)

Banno K, Kisu I, Yanokura M, Tsuji K, Masuda K, Ueki A, Kobayashi Y, Yamagami W, Nomura H, Susumu N *et al.* 2012 Progestin therapy for endometrial cancer: the potential of fourth-generation progestin (review). *International Journal of Oncology* **40** 1755–1762. (doi:10.3892/ijo.2012.1384)

Beleut M, Rajaram RD, Caikovski M, Ayyanan A, Germano D, Choi Y, Schneider P & Brisken C 2010 Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. *PNAS* **107** 2989–2994. (doi:10.1073/pnas.0915148107)

Beral V 2003 Breast cancer and hormone-replacement therapy in the Million Women Study. *Lancet* **362** 419–427. (doi:10.1016/S0140-6736(03)14596-5)

Boonyaratanakornkit V, Scott MP, Ribon V, Sherman L, Anderson SM, Maller JL, Miller WT & Edwards DP 2001 Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. *Molecular Cell* **8** 269–280. (doi:10.1016/S1097-2765(01)00304-5)

Boonyaratanakornkit V, McGowan E, Sherman L, Mancini MA, Cheskis BJ & Edwards DP 2007 The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle. *Molecular Endocrinology* **21** 359–375. (doi:10.1210/me.2006-0337)

Brisken C 2013 Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. *Nature Reviews. Cancer* **13** 385–396. (doi:10.1038/nrc3518)

Brisken C & O'Malley B 2010 Hormone action in the mammary gland. *Cold Spring Harbor Perspectives in Biology* **2** a003178. (doi:10.1101/cshperspect.a003178)

Brisken C, Park S, Vass T, Lydon JP, O'Malley BW & Weinberg RA 1998 A paracrine role for the epithelial progesterone receptor in mammary gland development. *PNAS* **95** 5076–5081. (doi:10.1073/pnas.95.9.5076)

Bu SZ, Yin DL, Ren XH, Jiang LZ, Wu ZJ, Gao QR & Pei G 1997 Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian carcinoma cell lines. *Cancer* **79** 1944–1950. (doi:10.1002/(SICI)1097-0142(19970515)79:10<1944::AID-CNCR15>3.0.CO;2-V)

Cancer Genome Atlas Research Network 2011 Integrated genomic analyses of ovarian carcinoma. *Nature* **474** 609–615. (doi:10.1038/nature10166)

Chabbert-Buffet N, Meduri G, Bouchard P & Spitz IM 2005 Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. *Human Reproduction Update* **11** 293–307. (doi:10.1093/humupd/dmi002)

Charles D 1964 Iatrogenic endometrial patterns. *Journal of Clinical Pathology* **17** 205–212. (doi:10.1136/jcp.17.3.205)

Chen B, Pan H, Zhu L, Deng Y & Pollard JW 2005 Progesterone inhibits the estrogen-induced phosphoinositide 3-kinase→AKT→GSK-3β→cyclin D1→pRB pathway to block uterine epithelial cell proliferation. *Molecular Endocrinology* **19** 1978–1990. (doi:10.1210/me.2004-0274)

Chlebowski RT & Anderson GL 2012 Changing concepts: menopausal hormone therapy and breast cancer. *Journal of the National Cancer Institute* **104** 517–527. (doi:10.1093/jnci/djs014)

Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, Aragaki AK, Ockene JK, Lane DS, Sarto GE *et al.* 2009 Breast cancer after use of estrogen plus progestin in postmenopausal women. *New England Journal of Medicine* **360** 573–587. (doi:10.1056/NEJMoa0807684)

Chodankar R, Kwang S, Sangiorgi F, Hong H, Yen HY, Deng C, Pike MC, Shuler CF, Maxson R & Dubeau L 2005 Cell-nonautonomous induction of ovarian and uterine serous cystadenomas in mice lacking a functional Brca1 in ovarian granulosa cells. *Current Biology* **15** 561–565. (doi:10.1016/j.cub.2005.01.052)

Chung HH, Sze SK, Tay AS & Lin VC 2014 Acetylation at lysine 183 of progesterone receptor by p300 accelerates DNA binding kinetics and transactivation of direct target genes. *Journal of Biological Chemistry* **289** 2180–2194. (doi:10.1074/jbc.M113.517896)

Chwalisz K, Larsen L, Mattia-Goldberg C, Edmonds A, Elger W & Winkel CA 2007 A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. *Fertility and Sterility* **87** 1399–1412.

Cicatiello L, Addeo R, Sasso A, Altucci L, Petrizzi VB, Borgo R, Cancemi M, Caporali S, Caristi S, Scafoglio C *et al.* 2004 Estrogens and progesterone promote persistent CCND1 gene activation during G1 by inducing transcriptional derepression via c-Jun/c-Fos/estrogen receptor (progesterone receptor) complex assembly to a distal regulatory element and recruitment of cyclin D1 to its own gene promoter. *Molecular and Cellular Biology* **24** 7260–7274. (doi:10.1128/MCB.24.16.7260-7274.2004)

Cittelly DM, Finlay-Schultz J, Howe EN, Spoelstra NS, Axlund SD, Hendricks P, Jacobsen BM, Sartorius CA & Richer JK 2013 Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4. *Oncogene* **32** 2555–2564. (doi:10.1038/onc.2012.275)

Clancy KB 2009 Reproductive ecology and the endometrium: physiology, variation, and new directions. *American Journal of Physical Anthropology* **140** (Suppl 49) 137–154. (doi:10.1002/ajpa.21188)

Clevers H 2006 Wnt/β-catenin signaling in development and disease. *Cell* **127** 469–480. (doi:10.1016/j.cell.2006.10.018)

Collaborative Group on Hormonal Factors in Breast Cancer 1996 Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. *Lancet* **347** 1713–1727. (doi:10.1016/S0140-6736(96)90806-5)

Condon JC, Hardy DB, Kovaric K & Mendelson CR 2006 Up-regulation of the progesterone receptor (PR)-C isoform in laboring myometrium by activation of nuclear factor-κB may contribute to the onset of labor through inhibition of PR function. *Molecular Endocrinology* **20** 764–775. (doi:10.1210/me.2005-0242)

Conneely OM, Mulac-Jericevic B, Lydon JP & De Mayo FJ 2001 Reproductive functions of the progesterone receptor isoforms: lessons from knock-out mice. *Molecular and Cellular Endocrinology* **179** 97–103. (doi:10.1016/S0303-7207(01)00465-8)

Conneely OM, Mulac-Jericevic B & Lydon JP 2003 Progesterone-dependent regulation of female reproductive activity by two distinct progesterone receptor isoforms. *Steroids* **68** 771–778. (doi:10.1016/S0039-128X(03)00126-0)

Cooke PS, Buchanan DL, Young P, Setiawan T, Brody J, Korach KS, Taylor J, Lubahn DB & Cunha GR 1997 Stromal estrogen receptors mediate mitogenic effects of estradiol on uterine epithelium. *PNAS* **94** 6535–6540. (doi:10.1073/pnas.94.12.6535)

Daniel AR & Lange CA 2009 Protein kinases mediate ligand-independent derepression of sumoylated progesterone receptors in breast cancer cells. *PNAS* **106** 14287–14292. (doi:10.1073/pnas.0905118106)

Daniel CW, Silberstein GB & Strickland P 1987 Direct action of 17β-estradiol on mouse mammary ducts analyzed by sustained release implants and steroid autoradiography. *Cancer Research* **47** 6052–6057.

Daniel AR, Faivre EJ & Lange CA 2007 Phosphorylation-dependent antagonism of sumoylation derepresses progesterone receptor action in breast cancer cells. *Molecular Endocrinology* **21** 2890–2906. (doi:10.1210/me.2007-0248)

Daniel AR, Knutson TP & Lange CA 2009 Signaling inputs to progesterone receptor gene regulation and promoter selectivity. *Molecular and Cellular Endocrinology* **308** 47–52. (doi:10.1016/j.mce.2009.01.004)

Daniel AR, Gaviglio AL, Czaplicki LM, Hillard CJ, Housa D & Lange CA 2010 The progesterone receptor hinge region regulates the kinetics of transcriptional responses through acetylation, phosphorylation, and nuclear retention. *Molecular Endocrinology* **24** 2126–2138. (doi:10.1210/me.2010-0170)

Daniel AR, Hagan CR & Lange CA 2011 Progesterone receptor action: defining a role in breast cancer. *Expert Review of Endocrinology & Metabolism* **6** 359–369. (doi:10.1586/eem.11.25)

Daniel AR, Gaviglio AL, Knutson TP, Ostrander JH, D'Assoro AB, Ravindranathan P, Peng Y, Raj GV, Yee D & Lange CA 2015

http://jme.endocrinology-journals.org
DOI: 10.1530/JME-14-0252

Published by Bioscientifica Ltd.

Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes. *Oncogene* **34** 506–515. (doi:10.1038/onc.2013.579)

DeManno D, Elger W, Garg R, Lee R, Schneider B, Hess-Stumpp H, Schubert G & Chwalisz K 2003 Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy. *Steroids* **68** 1019–1032.

Diep CH, Charles NJ, Gilks CB, Kalloger SE, Argenta PA & Lange CA 2013 Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells. *Cell Cycle* **12** 1433–1449. (doi:10.4161/cc.24550)

Dressing GE, Hagan CR, Knutson TP, Daniel AR & Lange CA 2009 Progesterone receptors act as sensors for mitogenic protein kinases in breast cancer models. *Endocrine-Related Cancer* **16** 351–361. (doi:10.1677/ERC-08-0281)

Dressing GE, Knutson TP, Schiewer MJ, Daniel AR, Hagan CR, Diep CH, Knudsen KE & Lange CA 2014 Progesterone receptor-cyclin d1 complexes induce cell cycle-dependent transcriptional programs in breast cancer cells. *Molecular Endocrinology* **28** 442–457. (doi:10.1210/me.2013-1196)

Edmondson RJ & Monaghan JM 2001 The epidemiology of ovarian cancer. *International Journal of Gynecological Cancer* **11** 423–429. (doi:10.1046/j.1525-1438.2001.01053.x)

Encarnacion CA, Ciocca DR, McGuire WL, Clark GM, Fuqua SA & Osborne CK 1993 Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. *Breast Cancer Research and Treatment* **26** 237–246. (doi:10.1007/BF00665801)

Engman M, Granberg S, Williams AR, Meng CX, Lalitkumar PG & Gemzell-Danielsson K 2009 Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. *Human Reproduction* **24** 1870–1879.

Faivre EJ & Lange CA 2007 Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells. *Molecular and Cellular Biology* **27** 466–480. (doi:10.1128/MCB.01539-06)

Faivre E, Skildum A, Pierson-Mullany L & Lange CA 2005 Integration of progesterone receptor mediated rapid signaling and nuclear actions in breast cancer cell models: role of mitogen-activated protein kinases and cell cycle regulators. *Steroids* **70** 418–426. (doi:10.1016/j.steroids.2005.02.012)

Faivre EJ, Daniel AR, Hillard CJ & Lange CA 2008 Progesterone receptor rapid signaling mediates serine 345 phosphorylation and tethering to specificity protein 1 transcription factors. *Molecular Endocrinology* **22** 823–837. (doi:10.1210/me.2007-0437)

Fan W, Yanase T, Morinaga H, Okabe T, Nomura M, Daitoku H, Fukamizu A, Kato S, Takayanagi R & Nawata H 2007 Insulin-like growth factor 1/insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor. *Journal of Biological Chemistry* **282** 7329–7338. (doi:10.1074/jbc.M610447200)

Fauvet R, Dufournet Etienne C, Poncelet C, Bringuier AF, Feldmann G & Darai E 2006 Effects of progesterone and anti-progestin (mifepristone) treatment on proliferation and apoptosis of the human ovarian cancer cell line, OVCAR-3. *Oncology Reports* **15** 743–748. (doi:10.3892/or.15.4.743)

Fleisch MC, Chou YC, Cardiff RD, Asaithambi A & Shyamala G 2009 Overexpression of progesterone receptor A isoform in mice leads to endometrial hyperproliferation, hyperplasia and atypia. *Molecular Human Reproduction* **15** 241–249. (doi:10.1093/molehr/gap013)

Folkins AK, Jarboe EA, Saleemuddin A, Lee Y, Callahan MJ, Drapkin R, Garber JE, Muto MG, Tworoger S & Crum CP 2008 A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. *Gynecologic Oncology* **109** 168–173. (doi:10.1016/j.ygyno.2008.01.012)

Fournier A, Berrino F, Riboli E, Avenel V & Clavel-Chapelon F 2005 Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. *International Journal of Cancer* **114** 448–454. (doi:10.1002/ijc.20710)

Fournier A, Berrino F & Clavel-Chapelon F 2008 Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. *Breast Cancer Research and Treatment* **107** 103–111. (doi:10.1007/s10549-007-9523-x)

Franco HL, Rubel CA, Large MJ, Wetendorf M, Fernandez-Valdivia R, Jeong JW, Spencer TE, Behringer RR, Lydon JP & Demayo FJ 2012 Epithelial progesterone receptor exhibits pleiotropic roles in uterine development and function. *FASEB Journal* **26** 1218–1227. (doi:10.1096/fj.11-193334)

Gabra H, Watson JE, Taylor KJ, Mackay J, Leonard RC, Steel CM, Porteous DJ & Smyth JF 1996 Definition and refinement of a region of loss of heterozygosity at 11q23.3–q24.3 in epithelial ovarian cancer associated with poor prognosis. *Cancer Research* **56** 950–954.

Giangrande PH, Kimbrel EA, Edwards DP & McDonnell DP 2000 The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding. *Molecular and Cellular Biology* **20** 3102–3115. (doi:10.1128/MCB.20.9.3102-3115.2000)

Giulianelli S, Vaque JP, Soldati R, Wargon V, Vanzulli SI, Martins R, Zeitlin E, Molinolo AA, Helguero LA, Lamb CA *et al.* 2012 Estrogen receptor α mediates progestin-induced mammary tumor growth by interacting with progesterone receptors at the cyclin D1/MYC promoters. *Cancer Research* **72** 2416–2427. (doi:10.1158/0008-5472.CAN-11-3290)

Goto T, Takano M, Hirata J & Tsuda H 2008 The involvement of FOXO1 in cytotoxic stress and drug-resistance induced by paclitaxel in ovarian cancers. *British Journal of Cancer* **98** 1068–1075. (doi:10.1038/sj.bjc.6604279)

Goyeneche AA & Telleria CM 2015 Antiprogestins in gynecological diseases. *Reproduction* **149** R15–R33. (doi:10.1530/REP-14-0416)

Graham JD & Clarke CL 1997 Physiological action of progesterone in target tissues. *Endocrine Reviews* **18** 502–519. (doi:10.1210/edrv.18.4.0308)

Graham JD, Mote PA, Salagame U, van Dijk JH, Balleine RL, Huschtscha LI, Reddel RR & Clarke CL 2009 DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast. *Endocrinology* **150** 3318–3326. (doi:10.1210/en.2008-1630)

Groshong SD, Owen GI, Grimison B, Schauer IE, Todd MC, Langan TA, Sclafani RA, Lange CA & Horwitz KB 1997 Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1). *Molecular Endocrinology* **11** 1593–1607. (doi:10.1210/mend.11.11.0006)

Gross GE, Clark GM, Chamness GC & McGuire WL 1984 Multiple progesterone receptor assays in human breast cancer. *Cancer Research* **44** 836–840.

Gupta A, Mehta R, Alimirah F, Peng X, Murillo G, Wiehle R & Mehta RG 2013 Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells. *Journal of Steroid Biochemistry and Molecular Biology* **133** 30–42.

Hagan CR & Lange CA 2014 Molecular determinants of context-dependent progesterone receptor action in breast cancer. *BMC Medicine* **12** 32. (doi:10.1186/1741-7015-12-32)

Hagan CR, Regan TM, Dressing GE & Lange CA 2011*a* ck2-dependent phosphorylation of progesterone receptors (PR) on Ser81 regulates PR-B isoform-specific target gene expression in breast cancer cells. *Molecular and Cellular Biology* **31** 2439–2452. (doi:10.1128/MCB.01246-10)

Hagan CR, Daniel AR, Dressing GE & Lange CA 2011*b* Role of phosphorylation in progesterone receptor signaling and specificity. *Molecular and Cellular Endocrinology* **357** 43–49. (doi:10.1016/j.mce.2011.09.017)

Hagan CR, Knutson TP & Lange CA 2013 A common docking domain in progesterone receptor-B links DUSP6 and CK2 signaling to proliferative transcriptional programs in breast cancer cells. *Nucleic Acids Research* **41** 8926–8942. (doi:10.1093/nar/gkt706)

Han SJ, Jeong J, Demayo FJ, Xu J, Tsai SY, Tsai MJ & O'Malley BW 2005 Dynamic cell type specificity of SRC-1 coactivator in modulating uterine progesterone receptor function in mice. *Molecular and Cellular Biology* **25** 8150–8165. (doi:10.1128/MCB.25.18.8150-8165.2005)

http://jme.endocrinology-journals.org
DOI: 10.1530/JME-14-0252

Published by Bioscientifica Ltd.

Han SJ, Tsai SY, Tsai MJ & O'Malley BW 2007 Distinct temporal and spatial activities of RU486 on progesterone receptor function in reproductive organs of ovariectomized mice. *Endocrinology* **148** 2471–2486. (doi:10.1210/en.2006-1561)

Hankinson SE, Colditz GA, Hunter DJ, Spencer TL, Rosner B & Stampfer MJ 1992 A quantitative assessment of oral contraceptive use and risk of ovarian cancer. *Obstetrics and Gynecology* **80** 708–714.

Hecht JL & Mutter GL 2006 Molecular and pathologic aspects of endometrial carcinogenesis. *Journal of Clinical Oncology* **24** 4783–4791. (doi:10.1200/JCO.2006.06.7173)

Hedrick SM, Hess Michelini R, Doedens AL, Goldrath AW & Stone EL 2012 FOXO transcription factors throughout T cell biology. *Nature Reviews. Immunology* **12** 649–661. (doi:10.1038/nri3278)

Helle SI, Jonat W, Giurescu M, Ekse D, Holly JM & Lonning PE 1998 Influence of treatment with onapristone on the IGF-system in breast cancer patients. *Journal of Steroid Biochemistry and Molecular Biology* **66** 159–163.

Hempling RE, Piver MS, Eltabbakh GH & Recio FO 1998 Progesterone receptor status is a significant prognostic variable of progression-free survival in advanced epithelial ovarian cancer. *American Journal of Clinical Oncology* **21** 447–451. (doi:10.1097/00000421-199810000-00005)

Hilton HN, Graham JD, Kantimm S, Santucci N, Cloosterman D, Huschtscha LI, Mote PA & Clarke CL 2012 Progesterone and estrogen receptors segregate into different cell subpopulations in the normal human breast. *Molecular and Cellular Endocrinology* **361** 191–201. (doi:10.1016/j.mce.2012.04.010)

Hogdall EV, Christensen L, Hogdall CK, Blaakaer J, Gayther S, Jacobs IJ, Christensen IJ & Kjaer SK 2007 Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study. *Oncology Reports* **18** 1051–1059. (doi:10.3892/or.18.5.1051)

Hong H, Yen HY, Brockmeyer A, Liu Y, Chodankar R, Pike MC, Stanczyk FZ, Maxson R & Dubeau L 2010 Changes in the mouse estrus cycle in response to BRCA1 inactivation suggest a potential link between risk factors for familial and sporadic ovarian cancer. *Cancer Research* **70** 221–228. (doi:10.1158/0008-5472.CAN-09-3232)

Horwitz KB & Sartorius CA 2008 Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis. *Journal of Clinical Endocrinology and Metabolism* **93** 3295–3298. (doi:10.1210/jc.2008-0938)

Horwitz KB, Dye WW, Harrell JC, Kabos P & Sartorius CA 2008 Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. *PNAS* **105** 5774–5779. (doi:10.1073/pnas.0706216105)

Hou X, Tan Y, Li M, Dey SK & Das SK 2004 Canonical Wnt signaling is critical to estrogen-mediated uterine growth. *Molecular Endocrinology* **18** 3035–3049. (doi:10.1210/me.2004-0259)

Hovland AR, Powell RL, Takimoto GS, Tung L & Horwitz KB 1998 An N-terminal inhibitory function, IF, suppresses transcription by the A-isoform but not the B-isoform of human progesterone receptors. *Journal of Biological Chemistry* **273** 5455–5460. (doi:10.1074/jbc.273.10.5455)

Hunter DJ, Colditz GA, Hankinson SE, Malspeis S, Spiegelman D, Chen W, Stampfer MJ & Willett WC 2010 Oral contraceptive use and breast cancer: a prospective study of young women. *Cancer Epidemiology, Biomarkers & Prevention* **19** 2496–2502. (doi:10.1158/1055-9965.EPI-10-0747)

Ioffe OB, Zaino RJ & Mutter GL 2009 Endometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulator. *Modern Pathology* **22** 450–459.

Janzen DM, Rosales MA, Paik DY, Lee DS, Smith DA, Witte ON, Iruela-Arispe ML & Memarzadeh S 2013 Progesterone receptor signaling in the microenvironment of endometrial cancer influences its response to hormonal therapy. *Cancer Research* **73** 4697–4710. (doi:10.1158/0008-5472.CAN-13-0930)

Jemal A, Bray F, Center MM, Ferlay J, Ward E & Forman D 2011 Global cancer statistics. *CA: A Cancer Journal for Clinicians* **61** 69–90. (doi:10.3322/caac.20107)

Jonat W, Bachelot T, Ruhstaller T, Kuss I, Reimann U & Robertson JF 2013 Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer. *Annals of Oncology* **24** 2543–2548.

Johnston SR, Saccani-Jotti G, Smith IE, Salter J, Newby J, Coppen M, Ebbs SR & Dowsett M 1995 Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. *Cancer Research* **55** 3331–3338.

Jones MC, Fusi L, Higham JH, Abdel-Hafiz H, Horwitz KB, Lam EW & Brosens JJ 2006 Regulation of the SUMO pathway sensitizes differentiating human endometrial stromal cells to progesterone. *PNAS* **103** 16272–16277. (doi:10.1073/pnas.0603002103)

Jongen V, Briet J, de Jong R, ten Hoor K, Boezen M, van der Zee A, Nijman H & Hollema H 2009 Expression of estrogen receptor-α and -β and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. *Gynecologic Oncology* **112** 537–542. (doi:10.1016/j.ygyno.2008.10.032)

Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, Clarke CL, Stingl J, Waterhouse PD & Khokha R 2010 Progesterone induces adult mammary stem cell expansion. *Nature* **465** 803–807. (doi:10.1038/nature09091)

Kaku T, Yoshikawa H, Tsuda H, Sakamoto A, Fukunaga M, Kuwabara Y, Hataeg M, Kodama S, Kuzuya K, Sato S *et al.* 2001 Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome. *Cancer Letters* **167** 39–48. (doi:10.1016/S0304-3835(01)00462-1)

Kariagina A, Aupperlee MD & Haslam SZ 2008 Progesterone receptor isoform functions in normal breast development and breast cancer. *Critical Reviews in Eukaryotic Gene Expression* **18** 11–33. (doi:10.1615/CritRevEukarGeneExpr.v18.i1.20)

Karst AM, Levanon K & Drapkin R 2011 Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. *PNAS* **108** 7547–7552. (doi:10.1073/pnas.1017300108)

Keith Bechtel M & Bonavida B 2001 Inhibitory effects of 17β-estradiol and progesterone on ovarian carcinoma cell proliferation: a potential role for inducible nitric oxide synthase. *Gynecologic Oncology* **82** 127–138. (doi:10.1006/gyno.2001.6221)

Khan JA, Tikad A, Fay M, Hamze A, Fagart J, Chabbert-Buffet N, Meduri G, Amazit L, Brion JD, Alami M *et al.* 2013 A new strategy for selective targeting of progesterone receptor with passive antagonists. *Molecular Endocrinology* **27** 909–924.

Khunamornpong S, Suprasert P, Chiangmai WN & Siriaunkgul S 2006 Metastatic tumors to the ovaries: a study of 170 cases in northern Thailand. *International Journal of Gynecological Cancer* **16** (Suppl 1) 132–138. (doi:10.1111/j.1525-1438.2006.00302.x)

Kim JJ & Chapman-Davis E 2010 Role of progesterone in endometrial cancer. *Seminars in Reproductive Medicine* **28** 81–90. (doi:10.1055/s-0029-1242998)

Kim JJ, Buzzio OL, Li S & Lu Z 2005 Role of FOXO1A in the regulation of insulin-like growth factor-binding protein-1 in human endometrial cells: interaction with progesterone receptor. *Biology of Reproduction* **73** 833–839. (doi:10.1095/biolreprod.105.043182)

Kim JJ, Kurita T & Bulun SE 2013 Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. *Endocrine Reviews* **34** 130–162. (doi:10.1210/er.2012-1043)

Klijn JG, de Jong FH, Bakker GH, Lamberts SW, Rodenburg CJ & Alexieva-Figusch J 1989 Antiprogestins, a new form of endocrine therapy for human breast cancer. *Cancer Research* **49** 2851–2856.

Knutson TP & Lange CA 2014 Tracking progesterone receptor-mediated actions in breast cancer. *Pharmacology & Therapeutics* **142** 114–125. (doi:10.1016/j.pharmthera.2013.11.010)

http://jme.endocrinology-journals.org
DOI: 10.1530/JME-14-0252

Published by Bioscientifica Ltd.

Knutson TP, Daniel AR, Fan D, Silverstein KA, Covington KR, Fuqua SA & Lange CA 2012*a* Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression. *Breast Cancer Research* **14** R95. (doi:10.1186/bcr3211)

Knutson TP, Daniel AR, Fan D, Silverstein KA, Covington KR, Fuqua SA & Lange CA 2012*b* Phosphorylated and small ubiquitin-like modifier protein-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression. *Breast Cancer Research* **14** R95. (doi:10.1186/bcr3211)

Kreizman-Shefer H, Pricop J, Goldman S, Elmalah I & Shalev E 2014 Distribution of estrogen and progesterone receptors isoforms in endometrial cancer. *Diagnostic Pathology* **9** 77. (doi:10.1186/1746-1596-9-77)

Kurita T, Young P, Brody JR, Lydon JP, O'Malley BW & Cunha GR 1998 Stromal progesterone receptors mediate the inhibitory effects of progesterone on estrogen-induced uterine epithelial cell deoxyribonucleic acid synthesis. *Endocrinology* **139** 4708–4713. (doi:10.1210/en.139.11.4708)

Kyo S, Sakaguchi J, Kiyono T, Shimizu Y, Maida Y, Mizumoto Y, Mori N, Nakamura M, Takakura M, Miyake K *et al*. 2011 Forkhead transcription factor FOXO1 is a direct target of progestin to inhibit endometrial epithelial cell growth. *Clinical Cancer Research* **17** 525–537. (doi:10.1158/1078-0432.CCR-10-1287)

Lange CA, Shen T & Horwitz KB 2000 Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. *PNAS* **97** 1032–1037. (doi:10.1073/pnas.97.3.1032)

Lee P, Rosen DG, Zhu C, Silva EG & Liu J 2005 Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. *Gynecologic Oncology* **96** 671–677. (doi:10.1016/j.ygyno.2004.11.010)

Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, Garber J, Birch C, Mou H, Gordon RW *et al*. 2007 A candidate precursor to serous carcinoma that originates in the distal fallopian tube. *Journal of Pathology* **211** 26–35. (doi:10.1002/path.2091)

Lenhard M, Tereza L, Heublein S, Ditsch N, Himsl I, Mayr D, Friese K & Jeschke U 2012 Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survival. *BMC Cancer* **12** 553. (doi:10.1186/1471-2407-12-553)

Leslie KK, Kumar NS, Richer J, Owen G, Takimoto G, Horwitz KB & Lange C 1997 Differential expression of the A and B isoforms of progesterone receptor in human endometrial cancer cells. Only progesterone receptor B is induced by estrogen and associated with strong transcriptional activation. *Annals of the New York Academy of Sciences* **828** 17–26. (doi:10.1111/j.1749-6632.1997.tb48520.x)

Levens ED, Potlog-Nahari C, Armstrong AY, Wesley R, Premkumar A, Blithe DL, Blocker W & Nieman LK 2008 CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. *Obstetrics and Gynecology* **111** 1129–1136.

Li P, Lee H, Guo S, Unterman TG, Jenster G & Bai W 2003 AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR. *Molecular and Cellular Biology* **23** 104–118. (doi:10.1128/MCB.23.1.104-118.2003)

Li Q, Kannan A, DeMayo FJ, Lydon JP, Cooke PS, Yamagishi H, Srivastava D, Bagchi MK & Bagchi IC 2011 The antiproliferative action of progesterone in uterine epithelium is mediated by Hand2. *Science* **331** 912–916. (doi:10.1126/science.1197454)

Li CI, Beaber EF, Tang MT, Porter PL, Daling JR & Malone KE 2012 Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of age. *Cancer Research* **72** 2028–2035. (doi:10.1158/0008-5472.CAN-11-4064)

Lindgren P, Backstrom T, Mahlck CG, Ridderheim M & Cajander S 2001 Steroid receptors and hormones in relation to cell proliferation and apoptosis in poorly differentiated epithelial ovarian tumors. *International Journal of Oncology* **19** 31–38. (doi:10.3892/ijo.19.1.31)

Lo AT, Mori H, Mott J & Bissell MJ 2012 Constructing three-dimensional models to study mammary gland branching morphogenesis and functional differentiation. *Journal of Mammary Gland Biology and Neoplasia* **17** 103–110. (doi:10.1007/s10911-012-9251-7)

Lydon JP, DeMayo FJ, Funk CR, Mani SK, Hughes AR, Montgomery CA Jr, Shyamala G, Conneely OM & O'Malley BW 1995 Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. *Genes and Development* **9** 2266–2278. (doi:10.1101/gad.9.18.2266)

Lyytinen HK, Dyba T, Ylikorkala O & Pukkala EI 2010 A case–control study on hormone therapy as a risk factor for breast cancer in Finland: intrauterine system carries a risk as well. *International Journal of Cancer* **126** 483–489. (doi:10.1002/ijc.24738)

Maillot G, Lacroix-Triki M, Pierredon S, Gratadou L, Schmidt S, Benes V, Roche H, Dalenc F, Auboeuf D, Millevoi S *et al*. 2009 Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth. *Cancer Research* **69** 8332–8340. (doi:10.1158/0008-5472.CAN-09-2206)

McCampbell AS, Broaddus RR, Loose DS & Davies PJ 2006 Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium. *Clinical Cancer Research* **12** 6373–6378. (doi:10.1158/1078-0432.CCR-06-0912)

Mendelson CR 2009 Minireview: fetal–maternal hormonal signaling in pregnancy and labor. *Molecular Endocrinology* **23** 947–954. (doi:10.1210/me.2009-0016)

Merlino AA, Welsh TN, Tan H, Yi LJ, Cannon V, Mercer BM & Mesiano S 2007 Nuclear progesterone receptors in the human pregnancy myometrium: evidence that parturition involves functional progesterone withdrawal mediated by increased expression of progesterone receptor-A. *Journal of Clinical Endocrinology and Metabolism* **92** 1927–1933. (doi:10.1210/jc.2007-0077)

Mesiano S, Chan EC, Fitter JT, Kwek K, Yeo G & Smith R 2002 Progesterone withdrawal and estrogen activation in human parturition are coordinated by progesterone receptor A expression in the myometrium. *Journal of Clinical Endocrinology and Metabolism* **87** 2924–2930. (doi:10.1210/jcem.87.6.8609)

Mesiano S, Wang Y & Norwitz ER 2011 Progesterone receptors in the human pregnancy uterus: do they hold the key to birth timing? *Reproductive Sciences* **18** 6–19. (doi:10.1177/1933719110382922)

Migliaccio A, Piccolo D, Castoria G, Di Domenico M, Bilancio A, Lombardi M, Gong W, Beato M & Auricchio F 1998 Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. *EMBO Journal* **17** 2008–2018. (doi:10.1093/emboj/17.7.2008)

Miyamoto T, Watanabe J, Hata H, Jobo T, Kawaguchi M, Hattori M, Saito M & Kuramoto H 2004 Significance of progesterone receptor-A and -B expressions in endometrial adenocarcinoma. *Journal of Steroid Biochemistry and Molecular Biology* **92** 111–118. (doi:10.1016/j.jsbmb.2004.07.007)

Modugno F, Laskey R, Smith AL, Andersen CL, Haluska P & Oesterreich S 2012 Hormone response in ovarian cancer: time to reconsider as a clinical target? *Endocrine-Related Cancer* **19** R255–R279. (doi:10.1530/ERC-12-0175)

Mote PA, Balleine RL, McGowan EM & Clarke CL 1999 Colocalization of progesterone receptors A and B by dual immunofluorescent histochemistry in human endometrium during the menstrual cycle. *Journal of Clinical Endocrinology and Metabolism* **84** 2963–2971. (doi:10.1210/jcem.84.8.5928)

Mote PA, Leary JA, Avery KA, Sandelin K, Chenevix-Trench G, Kirk JA, Clarke CL & kConFab Investigators 2004 Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A. *Genes, Chromosomes & Cancer* **39** 236–248. (doi:10.1002/gcc.10321)

Mote PA, Graham JD & Clarke CL 2007 Progesterone receptor isoforms in normal and malignant breast. *Ernst Schering Foundation Symposium Proceedings* **1** 77–107. (doi:10.1007/2789_2008_076)

http://jme.endocrinology-journals.org
DOI: 10.1530/JME-14-0252

Published by Bioscientifica Ltd.

Mulac-Jericevic B, Mullinax RA, DeMayo FJ, Lydon JP & Conneely OM 2000 Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. *Science* **289** 1751–1754. (doi:10.1126/science.289.5485.1751)

Munstedt K, Steen J, Knauf AG, Buch T, von Georgi R & Franke FE 2000 Steroid hormone receptors and long term survival in invasive ovarian cancer. *Cancer* **89** 1783–1791. (doi:10.1002/1097-0142(20001015)89:8<1783::AID-CNCR19>3.0.CO;2-D)

Musgrove EA, Lee CS & Sutherland RL 1991 Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor α, epidermal growth factor receptor, c-fos, and c-myc genes. *Molecular and Cellular Biology* **11** 5032–5043. (doi:10.1128.MCB.11.10.5032)

Myatt SS & Lam EW 2007 The emerging roles of forkhead box (Fox) proteins in cancer. *Nature Reviews. Cancer* **7** 847–859. (doi:10.1038/nrc2223)

Mylonas I, Jeschke U, Shabani N, Kuhn C, Kunze S, Dian D, Friedl C, Kupka MS & Friese K 2007 Steroid receptors ERα, ERβ, PR-A and PR-B are differentially expressed in normal and atrophic human endometrium. *Histology and Histopathology* **22** 169–176.

Need EF, Selth LA, Harris TJ, Birrell SN, Tilley WD & Buchanan G 2012 Research resource: interplay between the genomic and transcriptional networks of androgen receptor and estrogen receptor α in luminal breast cancer cells. *Molecular Endocrinology* **26** 1941–1952. (doi:10.1210/me.2011-1314)

Nickisch K, Nair HB, Kesavaram N, Das B, Garfield R, Shi SQ, Bhaskaran SS, Grimm SL & Edwards DP 2013 Synthesis and antiprogestational properties of novel 17-fluorinated steroids. *Steroids* **78** 909–919.

Norquist BM, Garcia RL, Allison KH, Jokinen CH, Kernochan LE, Pizzi CC, Barrow BJ, Goff BA & Swisher EM 2010 The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations. *Cancer* **116** 5261–5271. (doi:10.1002/cncr.25439)

Obata K, Morland SJ, Watson RH, Hitchcock A, Chenevix-Trench G, Thomas EJ & Campbell IG 1998 Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. *Cancer Research* **58** 2095–2097.

Owen GI, Richer JK, Tung L, Takimoto G & Horwitz KB 1998 Progesterone regulates transcription of the p21(WAF1) cyclin-dependent kinase inhibitor gene through Sp1 and CBP/p300. *Journal of Biological Chemistry* **273** 10696–10701. (doi:10.1074/jbc.273.17.10696)

Pathiraja TN, Shetty PB, Jelinek J, He R, Hartmaier R, Margossian AL, Hilsenbeck SG, Issa JP & Oesterreich S 2011 Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients. *Clinical Cancer Research* **17** 4177–4186. (doi:10.1158/1078-0432.CCR-10-2950)

Perrault D, Eisenhauer EA, Pritchard KI, Panasci L, Norris B, Vandenberg T & Fisher B 1996 Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study. *Journal of Clinical Oncology* **14** 2709–2712.

Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, Jindal S, Segara D, Jia L, Moore NL *et al.* 2009 Androgen receptor inhibits estrogen receptor-α activity and is prognostic in breast cancer. *Cancer Research* **69** 6131–6140. (doi:10.1158/0008-5472.CAN-09-0452)

Pieber D, Allport VC, Hills F, Johnson M & Bennett PR 2001 Interactions between progesterone receptor isoforms in myometrial cells in human labour. *Molecular Human Reproduction* **7** 875–879. (doi:10.1093/molehr/7.9.875)

Pierson-Mullany LK & Lange CA 2004 Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activatoin of cyclin-dependent protein kinase2. *Molecular and Cellular Biology* **24** 10542–10547. (doi:10.1128/MCB.24.24.10542-10557.2004)

Qiu M & Lange CA 2003 MAP kinases couple multiple functions of human progesterone receptors: degradation, transcriptional synergy, and nuclear association. *Journal of Steroid Biochemistry and Molecular Biology* **85** 147–157. (doi:10.1016/S0960-0760(03)00221-8)

Ramsey EM, Houston ML & Harris JW 1976 Interactions of the trophoblast and maternal tissues in three closely related primate species. *American Journal of Obstetrics and Gynecology* **124** 647–652.

Ramondetta LM, Johnson AJ, Sun CC, Atkinson N, Smith JA, Jung MS, Broaddus R, Iyer RB & Burke T 2009 Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma. *Cancer* **115** 1867–1874.

Ren Y, Liu X, Ma D, Feng Y & Zhong N 2007 Down-regulation of the progesterone receptor by the methylation of progesterone receptor gene in endometrial cancer cells. *Cancer Genetics and Cytogenetics* **175** 107–116. (doi:10.1016/j.cancergencyto.2007.02.002)

Richer JK, Lange CA, Manning NG, Owen G, Powell R & Horwitz KB 1998 Convergence of progesterone with growth factor and cytokine signaling in breast cancer. Progesterone receptors regulate signal transducers and activators of transcription expression and activity. *Journal of Biological Chemistry* **273** 31317–31326. (doi:10.1074/jbc.273.47.31317)

Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM & Horwitz KB 2002 Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. *Journal of Biological Chemistry* **277** 5209–5218. (doi:10.1074/jbc.M110090200)

Robertson JF, Willsher PC, Winterbottom L, Blamey RW & Thorpe S 1999 Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. *European Journal of Cancer* **35** 214–218.

Rocereto TF, Saul HM, Aikins JA Jr & Paulson J 2000 Phase II study of mifepristone (RU486) in refractory ovarian cancer. *Gynecologic Oncology* **77** 429–432.

Rocereto TF, Brady WE, Shahin MS, Hoffman JS, Small L, Rotmensch J & Mannel RS 2010 A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a gynecologic oncology group study. *Gynecologic Oncology* **116** 332–334. (doi:10.1016/j.ygyno.2009.10.071)

Romieu G, Maudelonde T, Ulmann A, Pujol H, Grenier J, Cavalie G, Khalaf S & Rochefort H 1987 The antiprogestin RU486 in advanced breast cancer: preliminary clinical trial. *Bulletin du Cancer* **74** 455–461.

Rudd MD, Gonzalez-Robayna I, Hernandez-Gonzalez I, Weigel NL, Bingman WE III & Richards JS 2007 Constitutively active FOXO1a and a DNA-binding domain mutant exhibit distinct co-regulatory functions to enhance progesterone receptor A activity. *Journal of Molecular Endocrinology* **38** 673–690. (doi:10.1677/JME-07-0017)

Sakaguchi H, Fujimoto J, Hong BL, Nakagawa Y & Tamaya T 2004 Drastic decrease of progesterone receptor form B but not A mRNA reflects poor patient prognosis in endometrial cancers. *Gynecologic Oncology* **93** 394–399. (doi:10.1016/j.ygyno.2004.01.042)

Salghetti SE, Caudy AA, Chenoweth JG & Tansey WP 2001 Regulation of transcriptional activation domain function by ubiquitin. *Science* **293** 1651–1653. (doi:10.1126/science.1062079)

Samarnthai N, Hall K & Yeh IT 2010 Molecular profiling of endometrial malignancies. *Obstetrics and Gynecology International* **2010** 162363. (doi:10.1155/2010/162363)

Sasaki M, Dharia A, Oh BR, Tanaka Y, Fujimoto S & Dahiya R 2001 Progesterone receptor B gene inactivation and CpG hypermethylation in human uterine endometrial cancer. *Cancer Research* **61** 97–102.

Sato N, Tsunoda H, Nishida M, Morishita Y, Takimoto Y, Kubo T & Noguchi M 2000 Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. *Cancer Research* **60** 7052–7056.

Schuur ER, Loktev AV, Sharma M, Sun Z, Roth RA & Weigel RJ 2001 Ligand-dependent interaction of estrogen receptor-α with members of the forkhead transcription factor family. *Journal of Biological Chemistry* **276** 33554–33560. (doi:10.1074/jbc.M105555200)

http://jme.endocrinology-journals.org
DOI: 10.1530/JME-14-0252

Published by Bioscientifica Ltd.

Shabani N, Kuhn C, Kunze S, Schulze S, Mayr D, Dian D, Gingelmaier A, Schindlbeck C, Willgeroth F, Sommer H *et al*. 2007 Prognostic significance of oestrogen receptor α (ERα) and β (ERβ), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. *European Journal of Cancer* **43** 2434–2444. (doi:10.1016/j.ejca.2007.08.014)

Shao R 2013 Progesterone receptor isoforms A and B: new insights into the mechanism of progesterone resistance for the treatment of endometrial carcinoma. *Ecancermedicalscience* **7** 381. (doi:10.3332/ecancer.2013.381)

Sieh W, Kobel M, Longacre TA, Bowtell DD, Defazio A, Goodman MT, Hogdall E, Deen S, Wentzensen N, Moysich KB *et al*. 2013 Hormone-receptor expression and ovarian cancer survival: an ovarian tumor tissue analysis consortium study. *Lancet. Oncology* **14** 853–862. (doi:10.1016/S1470-2045(13)70253-5)

Sinn BV, Darb-Esfahani S, Wirtz RM, Budczies J, Sehouli J, Chekerov R, Dietel M & Denkert C 2011 Evaluation of a hormone receptor-positive ovarian carcinoma subtype with a favourable prognosis by determination of progesterone receptor and oestrogen receptor 1 mRNA expression in formalin-fixed paraffin-embedded tissue. *Histopathology* **59** 918–927. (doi:10.1111/j.1365-2559.2011.04028.x)

Soini T, Hurskainen R, Grenman S, Maenpaa J, Paavonen J & Pukkala E 2014 Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. *Obstetrics and Gynecology* **124** 292–299. (doi:10.1097/AOG.0000000000000356)

Song LN, Coghlan M & Gelmann EP 2004 Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor. *Molecular Endocrinology* **18** 70–85. (doi:10.1210/me.2003-0189)

Spitz IM 2006 Progesterone receptor antagonists. *Current Opinion in Investigational Drugs* **7** 882–890.

Spitz IM & Bardin CW 1993 Mifepristone (RU 486) – a modulator of progestin and glucocorticoid action. *New England Journal of Medicine* **329** 404–412. (doi:10.1056/NEJM199308053290607)

Stoecklin E, Wissler M, Schaetzle D, Pfitzner E & Groner B 1999 Interactions in the transcriptional regulation exerted by Stat5 and by members of the steroid hormone receptor family. *Journal of Steroid Biochemistry and Molecular Biology* **69** 195–204. (doi:10.1016/S0960-0760(99)00052-7)

Syed V & Ho SM 2003 Progesterone-induced apoptosis in immortalized normal and malignant human ovarian surface epithelial cells involves enhanced expression of FasL. *Oncogene* **22** 6883–6890. (doi:10.1038/sj.onc.1206828)

Syed V, Ulinski G, Mok SC, Yiu GK & Ho SM 2001 Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. *Cancer Research* **61** 6768–6776.

Takamoto N, Zhao B, Tsai SY & DeMayo FJ 2002 Identification of Indian hedgehog as a progesterone-responsive gene in the murine uterus. *Molecular Endocrinology* **16** 2338–2348. (doi:10.1210/me.2001-0154)

Talbi S, Hamilton AE, Vo KC, Tulac S, Overgaard MT, Dosiou C, Le Shay N, Nezhat CN, Kempson R, Lessey BA *et al*. 2006 Molecular phenotyping of human endometrium distinguishes menstrual cycle phases and underlying biological processes in normo-ovulatory women. *Endocrinology* **147** 1097–1121. (doi:10.1210/en.2005-1076)

Tang HY, Lin HY, Zhang S, Davis FB & Davis PJ 2004 Thyroid hormone causes mitogen-activated protein kinase-dependent phosphorylation of the nuclear estrogen receptor. *Endocrinology* **145** 3265–3272. (doi:10.1210/en.2004-0308)

Tangjitgamol S, Manusirivithaya S, Khunnarong J, Jesadapatarakul S & Tanwanich S 2009 Expressions of estrogen and progesterone receptors in epithelial ovarian cancer: a clinicopathologic study. *International Journal of Gynecological Cancer* **19** 620–627. (doi:10.1111/IGC.0b013e3181a44b62)

Tanos T, Sflomos G, Echeverria PC, Ayyanan A, Gutierrez M, Delaloye JF, Raffoul W, Fiche M, Dougall W, Schneider P *et al*. 2013 Progesterone/RANKL is a major regulatory axis in the human breast. *Science Translational Medicine* **5** 182ra155. (doi:10.1126/scitranslmed.3005654)

Tong W & Pollard JW 1999 Progesterone inhibits estrogen-induced cyclin D1 and cdk4 nuclear translocation, cyclin E- and cyclin A-cdk2 kinase activation, and cell proliferation in uterine epithelial cells in mice. *Molecular and Cellular Biology* **19** 2251–2264.

Tora L, Gronemeyer H, Turcotte B, Gaub MP & Chambon P 1988 The N-terminal region of the chicken progesterone receptor specifies target gene activation. *Nature* **333** 185–188. (doi:10.1038/333185a0)

Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T, Nakanishi T, Sasaki H, Saji F, Iwasaka T *et al*. 2007 Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. *Journal of Clinical Oncology* **25** 2798–2803. (doi:10.1200/JCO.2006.08.8344)

Vegeto E, Shahbaz MM, Wen DX, Goldman ME, O'Malley BW & McDonnell DP 1993 Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. *Molecular Endocrinology* **7** 1244–1255. (doi:10.1210/mend.7.10.8264658)

Venkitaraman AR 2002 Cancer susceptibility and the functions of BRCA1 and BRCA2. *Cell* **108** 171–182. (doi:10.1016/S0092-8674(02)00615-3)

Wang S, Counterman LJ & Haslam SZ 1990 Progesterone action in normal mouse mammary gland. *Endocrinology* **127** 2183–2189. (doi:10.1210/endo-127-5-2183)

Wang Y, Hanifi-Moghaddam P, Hanekamp EE, Kloosterboer HJ, Franken P, Veldscholte J, van Doorn HC, Ewing PC, Kim JJ, Grootegoed JA *et al*. 2009 Progesterone inhibition of Wnt/β-catenin signaling in normal endometrium and endometrial cancer. *Clinical Cancer Research* **15** 5784–5793. (doi:10.1158/1078-0432.CCR-09-0814)

Wang Y, van der Zee M, Fodde R & Blok LJ 2010 Wnt/β-catenin and sex hormone signaling in endometrial homeostasis and cancer. *Oncotarget* **1** 674–684.

Ward EC, Hoekstra AV, Blok LJ, Hanifi-Moghaddam P, Lurain JR, Singh DK, Buttin BM, Schink JC & Kim JJ 2008 The regulation and function of the forkhead transcription factor, Forkhead box O1, is dependent on the progesterone receptor in endometrial carcinoma. *Endocrinology* **149** 1942–1950. (doi:10.1210/en.2007-0756)

Wetendorf M & DeMayo FJ 2012 The progesterone receptor regulates implantation, decidualization, and glandular development via a complex paracrine signaling network. *Molecular and Cellular Endocrinology* **357** 108–118. (doi:10.1016/j.mce.2011.10.028)

Widschwendter M, Rosenthal AN, Philpott S, Rizzuto I, Fraser L, Hayward J, Intermaggio MP, Edlund CK, Ramus SJ, Gayther SA *et al*. 2013 The sex hormone system in carriers of BRCA1/2 mutations: a case–control study. *Lancet. Oncology* **14** 1226–1232. (doi:10.1016/S1470-2045(13)70448-0)

Wu Q, Ishikawa T, Sirianni R, Tang H, McDonald JG, Yuhanna IS, Thompson B, Girard L, Mineo C, Brekken RA *et al*. 2013 27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth. *Cell Reports* **5** 637–645. (doi:10.1016/j.celrep.2013.10.006)

Xiong Y, Dowdy SC, Gonzalez Bosquet J, Zhao Y, Eberhardt NL, Podratz KC & Jiang SW 2005 Epigenetic-mediated upregulation of progesterone receptor B gene in endometrial cancer cell lines. *Gynecologic Oncology* **99** 135–141. (doi:10.1016/j.ygyno.2005.05.035)

Yamaji D, Na R, Feuermann Y, Pechhold S, Chen W, Robinson GW & Hennighausen L 2009 Development of mammary luminal progenitor cells is controlled by the transcription factor STAT5A. *Genes and Development* **23** 2382–2387. (doi:10.1101/gad.1840109)

Yang XY, Xi MR, Yang KX & Yu H 2009 Prognostic value of estrogen receptor and progesterone receptor status in young Chinese ovarian carcinoma patients. *Gynecologic Oncology* **113** 99–104. (doi:10.1016/j.ygyno.2008.12.018)

Yang S, Thiel KW & Leslie KK 2011 Progesterone: the ultimate endometrial tumor suppressor. *Trends in Endocrinology and Metabolism* **22** 145–152. (doi:10.1016/j.tem.2011.01.005)

Yang S, Xiao X, Jia Y, Liu X, Zhang Y, Wang X, Winters CJ, Devor EJ, Meng X, Thiel KW *et al*. 2014 Epigenetic modification restores functional PR expression in endometrial cancer cells. *Current Pharmaceutical Design* **20** 1874–1880. (doi:10.2174/13816128113199990532)

http://jme.endocrinology-journals.org
DOI: 10.1530/JME-14-0252

Published by Bioscientifica Ltd.

Yang-Hartwich Y, Gurrea-Soteras M, Sumi N, Joo WD, Holmberg JC, Craveiro V, Alvero AB & Mor G 2014 Ovulation and extra-ovarian origin of ovarian cancer. *Scientific Reports* **4** 6116. (doi:10.1038/srep06116)

Yen HY, Gabet Y, Liu Y, Martin A, Wu NL, Pike MC, Frenkel B, Maxson R & Dubeau L 2012 Alterations in Brca1 expression in mouse ovarian granulosa cells have short-term and long-term consequences on estrogen-responsive organs. *Laboratory Investigation* **92** 802–811. (doi:10.1038/labinvest.2012.58)

Yerushalmi GM, Gilboa Y, Jakobson-Setton A, Tadir Y, Goldchmit C, Katz D & Seidman DS 2014 Vaginal mifepristone for the treatment of symptomatic uterine leiomyomata: an open-label study. *Fertility and Sterility* **101** 496–500.

Yu S, Lee M, Shin S & Park J 2001 Apoptosis induced by progesterone in human ovarian cancer cell line SNU-840. *Journal of Cellular Biochemistry* **82** 445–451. (doi:10.1002/jcb.1171)

Yudt MR, Russo LA, Berrodin TJ, Jelinsky SA, Ellis D, Cohen JC, Cooch N, Haglund E, Unwalla RJ, Fensome A *et al*. 2011 Discovery of a novel mechanism of steroid receptor antagonism: WAY-255348 modulates progesterone receptor cellular localization and promoter interactions. *Biochemical Pharmacology* **82** 1709–1719.

Yudt MR, Berrodin TJ, Jelinsky SA, Hanna LA, Brown EL, Chippari S, Bhat RA, Winneker RC & Zhang Z 2006 Selective and opposing actions of progesterone receptor isoforms in human endometrial stromal cells. *Molecular and Cellular Endocrinology* **247** 116–126. (doi:10.1016/j.mce.2005.12.012)

Zhang PJ, Zhao J, Li HY, Man JH, He K, Zhou T, Pan X, Li AL, Gong WL, Jin BF *et al*. 2007 CUE domain containing 2 regulates degradation of progesterone receptor by ubiquitin-proteasome. *EMBO Journal* **26** 1831–1842. (doi:10.1038/sj.emboj.7601602)

Received in final form 15 December 2014
Accepted 12 January 2015
Accepted Preprint published online 13 January 2015

http://jme.endocrinology-journals.org
DOI: 10.1530/JME-14-0252

Published by Bioscientifica Ltd.